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ABSTRACT
This research centers around a tylophorine analogue, DCB-3503, a lead compound that
possesses potent growth inhibitory activities against all 60 human-derived cell lines screened by
the National Cancer Institute (NCI). In comparison with other known antitumor compounds
using the NCI’s COMPARE analysis, it is apparent that the compound is acting through a unique
mechanism—one decidedly different from that of other known anticancer drugs. Additionally
DCB-3503 has shown inhibitory activities against HepG2 (human hepatocellular cancer, HCC),
PANC-1 (human pancreatic ductal carcinoma) and chemotherapeutic-resistant KB cell lines in
the hands of our collaborator, Dr. Yung-Chi Cheng of Yale University School of Medicine. In
order to predict structure–activity relationships, a Comparative Molecular Field Analysis
(CoMFA) model was constructed, and several DCB-3503 analogues with higher projected
antitumor activities were designed. These analogues included those with modifications at
positions 3 and 7, with CoMFA indicating greatest tolerance at the 3-position. Results from
biological studies suggested that a more complicated mechanism with different pathways for
different analogues was operative. A biotinylated DCB-3503 analogue that was designed and
synthesized previously in Dr. David Baker’s lab was utilized by our Yale collaborators to snare a
protein targeted by DCB-3503 type compounds. A cellular heat shock cognate protein 70 (Hsc70)
was identified as one of the target proteins of DCB-3503 in an anti-hepatitis C virus (HCV) study.
The target protein was then synthesized without and with 15N [nitrogen-15] labeling in our lab,
and the thermodynamic and NMR studies of its interactions with DCB-3503 were carried out.
However, failure to elucidate the specific DCB-3503 and Hsc70 interactions by NMR studies
prompted us to turn to computational simulations, where two docking models, including the one

v

based on DCB-3503 and the ATP-state Hsc70 nucleotide binding domain (NBD), and another
based on DCB-3503 and the apo-state Hsc70 NBD, were constructed. The most reasonable
docking pose of DCB-3503 was generated in the ATP-state protein based on the analysis of both
the experimental observations and the docking scores. Design of more promising active
candidates can likely be realized in the future through the study of the aforementioned docking
pose.
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INTRODUCTION
Tylophorine analogues are a group of phenanthroindolizidine alkaloids originally isolated
from an Indian native plant, Tylophora indica.5 Since their first isolation they have continued to
be the targets of synthesis, modification and structure–activity relationship (SAR) studies.6 In
this research the modifications of a hydroxylated (+)-S-tylophorine analogue, DCB-3503, which
is considered as a promising active anti-cancer drug candidate, was described. In the first part of
this research, a ligand-based design was performed via Comparative Molecular Field Analysis
(CoMFA) molecular modeling program. Several novel molecules designed based on DCB-3503
via CoMFA were synthesized and characterized, and their corresponding biological activities
were tested. In the second part of this research, a structure-based approach was carried out using
a biochemical probe molecule derived from DCB-3503. A protein involved in the development
of hepatitis C virus (HCV) infection was identified as one of the target proteins for DCB-3503,
and the overexpression and purification of this protein was carried out. The corresponding
thermodynamic and NMR studies of the interactions between the ligand and the protein were
performed. A docking model was then constructed with the aim of designing novel tylophorine
analogues with improved efficacy against HCV.
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PART ONE. THE LIGAND-BASED APPROACH
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ABSTRACT
The ligand-based approach is centered around a tylophorine analogue, DCB-3503, a lead
compound that possesses potent growth inhibitory activities against all 60 human-derived cell
lines screened by the National Cancer Institute (NCI). Compared with other known antitumor
compounds according to the NCI’s COMPARE analysis, it is obvious that the compound is
acting through a unique mechanism—one decidedly different from that of other known
anticancer drugs. Additionally DCB-3503 has shown inhibitory activities against HepG2 (human
hepatocellular cancer, HCC), PANC-1 (human pancreatic ductal carcinoma) and
chemotherapeutic-resistant KB cell lines in the hands of our collaborator, Dr. Yung-Chi Cheng
of Yale University School of Medicine. In order to aid in predicting structure–activity
relationships, a Comparative Molecular Field Analysis (CoMFA) model was constructed, and
several novel DCB-3503 analogues with higher projected antitumor activities were designed.
These analogues included those with modifications at positions 3 and 7. CoMFA analysis
suggested greatest tolerance for modifications at the 3-position. These novel DCB-3503
analogues were synthesized via a modification of a novel route, and the results from biological
studies suggested that a more complicated mechanism with different pathways for different
analogues was operative.
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I. BACKGROUND
1. The Tylophorine Analogues and DCB-3503.
Tylophorine analogues are a group of phenanthroindolizidine alkaloids originally isolated
from an Indian native plant, Tylophora indica.5 Since their first isolation they have continued to
be the targets of synthesis, modification and structure–activity relationship (SAR) studies
because of their diverse pharmacological activities. DCB-3503, a hydroxylated (+)-S-tylophorine
analogue, was recently derived and synthesized in Dr. Baker’s lab and is considered as a
promising active anti-cancer drug candidate.6

(+)-S-tylophorine

DCB-3503

Figure 1. The structures of (+)-S-tylophorine and DCB-3503.

2. The Biological Evaluation of Tylophorine Analogues.
A great number of investigations have been carried out on these tylophorine analogues after
their first isolation, and our studies were mainly focused on (+)-S-tylophorine and DCB-3503. In
4

the antitumor evaluation performed by National Cancer Institute (NCI), the two abovementioned compounds showed a consistent and potent growth inhibitory activity (GI50 ~ 10-8 M)
against all 60 human-derived cell lines including some refractory cell lines such as lung cancer
and melanoma cell lines. Furthermore, the COMPARE analysis of these two compounds
conducted by the NCI showed a unique antitumor mechanism in comparison with other known
antitumor compounds in clinical use.7 In the most recent studies carried out in Dr. Yung-Chi
Cheng’s lab at the School of Medicine of Yale University, the above two compounds also
showed a potent activity, both in vitro and in vivo, against the HepG2 (human hepatocellular
cancer, HCC) cell line, which was not included in the 60 cell lines screened by NCI. However a
discrepancy was discovered between the in vitro and in vivo activities against HepG2 cell line of
these two compounds, as (+)-S-tylophorine was more active than DCB-3503 in vitro, while
DCB-3503 was more active than (+)-S-tylophorine in vivo.7 In addition, DCB-3503 was also able
to suppress the activity of PANC-1 (human pancreatic ductal carcinoma) cell line and the
chemotherapeutic resistant KB cell line with the overexpression of multidrug resistance and
multidrug resistance-associated proteins.7, 8 Further investigations on other biological activities
were also carried out, as DCB-3503 was found to significantly suppress the development and
progression of collagen-induced arthritis (CIA) and to abrogate the skin disease in systemic
lupus erythematosus (SLE).9, 10

3. The Studies of the Mechanisms of Tylophorine Analogues.
It was believed the tylophorine analogues functioned through distinct mechanisms from the
most current antitumor compounds, since they did not induce DNA damage, did not inhibit DNA
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synthesis, and did not perturbate tubulin function according to the fact of failing to induce the
protein p53 as the sensor of DNA damage after the treatment of DCB-3503.7
Further experiments revealed that the tylophorine analogues were able to inhibit nuclear
factor-kappa B (NF-κB) pathway. NF-κB is a transcription factor that plays a vital role in
inflammation and cell survival, and its overexpression is believed to be one mechanism of
chemoresistance, as its activation will lead to the tumor cell survival, while its suppression will
stimulate an apoptotic response.11 The NF-κB transcription factor, which is usually constituted of
proteins p65 and p50 as a heterodimer, is usually tightly regulated by interactions with inhibitory
IκB proteins in the cytoplasm as an inactive complex. However, by activating the IκB kinase
(IKK) via an upstream signal, the IκB proteins regulating the NF-κB heterodimer will be
phosphorylated and further ubiquitinated and degraded, making the NF-κB heterodimer no
longer regulated and free to enter the nucleus to activate specific target gene expression. In the
meantime, the p65 is stimulated by phosphorylation as well, resulting in the transactivation of
target genes in cooperation with other transcriptional regulators.8, 12 It was found in Dr. Cheng’s
lab that after treatment with DCB-3503, the level of the phosphorylated p65 in cells decreased,
suggesting a mechanism not through preventing NF-κB from binding to DNA, but, at least in
part, through the degradation of the phosphorylated p65. Additionally DCB-3503 was able to
down-regulate IKKa, which is a subunit of IKK, and ultimately deactivate the NF-κB
heterodimer by preventing the phosphorylation of IκB proteins. Further study also indicated that
IKK was responsible for the phosphorylation of p65, meaning the suppression of IKK by DCB3503 can lead to the decreased level of phosphorylated p65, which eventually suppresses the
activation of the NF-κB pathway.8 The inhibitory effect of DCB-3503 on the NF-κB pathway
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may also explain its activity against CIA and the skin disease in SLE, as both of them are
generated partly by the inflammation caused via activation of the NF-κB pathway.9, 10
In a most recent study, it was found DCB-3503 was able to down-regulate a subset of
proteins including cyclin D1 that play a key role during cell-cycle progress from the G1 to the S
phase. The overexpression of this group of proteins was found in many human tumor cells and
was believed to be associated with chemoresistance in chemotherapy.11 Further investigation
showed the expression of cyclin D1 could be down-regulated in the first 15 min after the
treatment of DCB-3503, and no cell type-specification was observed. Cheng’s group then
concluded that DCB-3503 was capable of inhibiting the synthesis of a protein with a short halflife, such as cyclin D1, via reducing the polypeptide chain elongation rate. Therefore, this
mechanism of down-regulation of such proteins at the translational level truly makes DCB-3503
distinct from many current protein inhibitors and may serve to overcome chemoresistance in
chemotherapy.13
Although the studies mentioned above presented several possible mechanisms, SAR studies
on different tylophorine analogues with a variety of substituents and core groups showed the
possible existence of other targets or mechanisms, and the unique mechanisms of a given
tylophorine analogue might be far more complicated than what had been unveiled. The biologists
were led to declare that structural similarity in these compounds may not be associated with
similar modes of action—a perplexing situation for the medicinal chemists.11, 14-18

4. The Previous Synthesis of DCB-3503 and Its Analogues.
DCB-3503 was previously synthesized in Dr. Baker’s lab utilizing a modified route from its
first synthesis reported by Rapoport, and its anticancer activities were firstly tested by Baker
7

group in collaboration with NCI.3, 6, 19, 20 The detailed modified synthesis is shown in Scheme 1.
The key steps include a Perkin reaction, a FeCl 3 -mediated ring closure reaction, and a
stereoselective reduction of the ketone utilizing K-Selectride®.
Several DCB-3503 analogues were also synthesized, and the most important one was the
propargyl group-modified DCB-3503 (DCB-3509), which provided the possibility to further
synthesize the biotinylated DCB-3503 via copper-catalyzed azide–alkyne cycloaddition (CuAAC)
click chemistry. The key modification involved the introduction of the propargyl group, not only
as the moiety in the DCB-3509, but also as the protective group in the FeCl3 -mediated ringclosure step.2
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Scheme 1. The previous synthetic route of DCB-3503.3
9

Scheme 2. The previous synthetic route to DCB-3509.2
10

II. STATEMENT OF THE PROBLEM
1. The Screening of Novel DCB-3503 Analogues.
In order to design molecules with higher biological activities, the screening of novel DCB3503 analogues in silico was determined to be the first step in our approach. However due to the
lack of specific targets of DCB-3503 according to the previous biological studies, a structurebased approach was not possible, so a ligand-based approach was selected. With a variety of
tylophorine analogues possessing different structures and the corresponding biological activity
data, the Comparative Molecular Field Analysis (CoMFA), which is a 3D quantitative structure–
activity relationship (3D-QSAR) program, was selected as to derive potential candidate
compounds. The CoMFA model would be constructed, and the newly designed DCB-3503
analogues would be tested in the model, and selection would be made based on the predicted
activities.

2. The Synthesis of the Selected Novel DCB-3503 Analogues.
Several DCB-3503 analogues with more potential activities would be selected as the
synthetic target molecules. A newly reported route to synthesize the indolizidine moiety of DCB3503 shown in Scheme 3 would be attempted on the synthesis of the newly selected analogues. 1
The introduction of the novel route not only enabled one to reduce the overall steps of the
synthesis, but also realized the possibility to modify the molecule with more sensitive groups due
to the removal of the harsh reduction conditions at the last step in the previous synthetic route.

11

Scheme 3. The reported modifications of synthesis of DCB-3503.1
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III. DISCUSSION
1. The Construction of Novel CoMFA Models of Tylophorine
Analogues.
1.1. The Previous Ligand-Based Approach of Designing Novel
Tylophorine Analogues.
Several groups including our own home carried out the syntheses and structure–activity
relationship (SAR) studies on different structural analogues of tylophorine.11, 14-18 In order to
evaluate and screen novel DCB analogues in a better and faster approach, a CoMFA model was
built in Dr. Baker’s lab utilizing SYBYL 8.0 program.3 CoMFA is a 3D quantitative structure–
activity relationship (3D-QSAR) technique that is able to provide predictions of the behavior of
newly designed compounds based on their analogues with known activities when the specific
targets or mechanisms are unknown.21, 22 In the CoMFA model previously established, a group of
structural analogues of tylophorine with biological activities (GI 50 against HepG2 cells) is shown
in Figure 2.3 These were selected as the training set for construction of the new model. A
minimum of 10 molecules with a variety of different structures sharing a common structural core
is necessary for building a reliable model in CoMFA. Each of the structures was superposed on
the common core shown in Figure 3 to give an alignment, which was then embedded on a grid
with a spacing of 2 Å. The steric and electrostatic fields of the alignment were calculated by a
probe atom using Lennard–Jones potentials and coulombic potentials respectively, and were
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Figure 2. The group of molecules selected as the training set in the previous
CoMFA model.

14

Figure 3. The common structural
core of the alignment of the training
set molecules.
Figure 4. The alignment of the training set
molecules.

afterwards correlated with the biological data shown in Table 1. After the validation of the model
by Partial Least Squares (PLS) analysis, two contour maps were generated providing the future
modification directions as shown in Figure 5 using (+)-(S)-tylophorine as a template, where a
sterically bulky group was favored in the green area and disfavored in the yellow area, and
negatively charged groups or H-bond acceptors would enhance the biological activity in the red
area, whereas positively charged ones or H-bond donors were beneficial to the blue area. With
the assistance from the contour maps the corresponding modifications could be made and the
newly designed molecules were put into the CoMFA model for more accurate predictions on
their biological activities. The synthetic targets could then be selected from the molecules with
the highest predicted biological activities according to the CoMFA model.

15

Table 1. The biological data of the corresponding training set molecules.

(+)-(S)-tylophorine
(-)-(R)-tylophorine
(-)-antofine
(R)-cryptopleurine
(S)-cryptopleurine
(-)-ficuseptine C
PBT# 28
PBT# 31
PBT# 32
PBT# 33
PBT# 34

HepG2 GI50 (nM)
11 ± 4
33 ± 2
4.9 ± 0.4
1.5 ± 0.2
1.5 ± 0.2
371 ± 27
HepG2 GI50 (μM)
2.3 ± 0.3
8.6 ± 3.6
5.4 ± 1.4
3 ± 0.7
3.1 ± 1.0

HepG2 pGI50
7.959
7.481
8.310
8.824
8.824
6.431
5.638
5.066
5.268
5.523
5.509

Figure 5. The contour maps of the CoMFA model. (Red area: negative charge
and H-bond acceptors favored; Blue area: positive charge and H-bond donor
favored; Green area: steric bulky groups favored; Yellow area: Steric bulky
groups disfavored.)
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1.2. The Construction of a Novel CoMFA Model.
In the most recent studies it was revealed that the molecules used in the training set in the
previous CoMFA model, although they are structural analogues, may not be the functional
analogues.14, 15, 18 That is, their mechanisms of action may differ. According to the relative
studies, the modifications on the A ring or E ring of (−)-antofine shown in Figure 6 resulted in
compounds with two distinctive biological mechanisms compared with the original (−)-antofine
one, and similar results were obtained on DCB-3503 and rac-cryptopleurine as well.
Furthermore, either the expansion of the ring with different atoms or the modifications on the
same ring with different functional groups or different chiralities would result in different
mechanisms, indicating the possible existence of multi-mechanism and multi-targets of the
tylophorine analogues.14, 15 However, on the basis of the criteria of building a reliable CoMFA,
the molecules selected as the training set, of which the specific mechanism or target may be
unclear, should at least function through the same mechanism or on the same target.22 Therefore,
the previous CoMFA model built based on a group of different functional analogues with
different targets in the HepG2 cells was considered as not quite satisfactory, and a new CoMFA
model utilizing the molecules believed to target the same pathway (NF-κB pathway) as the
training set was constructed.

Figure 6. The structure of (−)-antofine.
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Figure 7. The molecules constituting of the training set in the novel CoMFA model.
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As can be seem in Figure 7, 11 molecules screened in Dr. Cheng’s lab that appeared via
appropriate assays to target the NF-κB pathway were selected as the training set for the novel
CoMFA model, and among them (S)-cryptopleurine and (R)-cryptopleurine were regarded
separately with equal biological activity as they were tested as a racemic mixture. 11, 14
The 11 molecules were firstly sketched in the SYBYL-X 2.1 program had MMFF94
charges assigned, and were energy minimized utilizing the MMFF94s force field. Then the
alignment of all the molecules was carried out using a slightly different common core from the
one used in the previous model due to the different positions of oxygens on the phenanthrene
ring. Manual correction of the alignment on the methoxy groups was necessary if they were not
in the same plane of the phenanthrene ring. Afterwards, the corresponding biological data, which
are shown in Table 2 as IC50 vs. NF-κB pathway, were firstly converted to the corresponding
−log units on an M-1 scale before application in the model. The steric and electrostatic fields of
the alignment were then calculated using the Tripos Standard Force Field, and the biological data
were correlated to these fields.

Figure 8. The common structural core
of the alignment of the training set
molecules in the novel CoMFA model.
Figure 9. The alignment of the training set
molecules in the novel CoMFA model.
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Table 2. The corresponding biological data of the training set molecules in the novel
CoMFA model.

(+)-(S)-tylophorine
(-)-(R)-tylophorine
(-)-antofine
(R)-cryptopleurine
(S)-cryptopleurine
DCB-3501
DCB-3506
DCB-3503
PA-5
PA-6
PA-7

NF-κB IC50 (nM)
41 ± 20
317 ± 51
7.3 ± 1.9
1.4 ± 0.6
1.4 ± 0.6
315 ± 64
322 ± 19
87 ± 6
11 ± 6
12 ± 9
10 ± 4

NF-κB pIC50
7.387
6.499
8.137
8.854
8.854
6.502
6.492
7.060
7.959
7.921
8.000

The validation of the model was carried out by running Partial Least Squares (PLS) analysis.
A leave-one-out (LOO) cross-validation and a non-cross-validation were performed to give the
correlated statistics. The q2 resulted from the LOO cross-validation was an indication of the
predictive abilities of the model and a value larger than 0.5 proves the robustness of the model.23
The conventional correlation coefficient r2 , which was typically much larger than q2, was
obtained from the non-cross-validation providing the quality of the fit of the calculated data and
observed data. The q2, r2 and the standard error of this newly built model were 0.570, 0.926 and
0.270, respectively, with an optimal number of components of 2, suggesting good predictive
power.24 The detailed CoMFA model calculation results are listed in Table 3.
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1.3. The Screening and Designing of Novel DCB-3503 Analogues.
With the newly constructed model in hand, two contour maps were derived as shown in
Figure 10 utilizing (+)-(S)-tylophorine as the template.
Based on the interpretation illustrated in the previous explanation of contour maps, several
DCB-3503 analogues were designed aiming at decreasing the volume at the 7-position of the
phenanthrene ring and increasing the volume at the 3-position as well as providing possible Hbond acceptors.
In order to decrease the volume of the substituent at the 7-position, hydrogen and halogens
were considered as good candidates. Since similar hydrogen-substituted DCB-3503 at 6- and 7positions has been synthesized and studied in Dr. Baker’s lab, therefore only halogen substituted
analogues were designed. However, in consideration of avoiding the addition of H-bond
acceptors, only chlorine and bromine modified analogues were tested in the CoMFA model.
Another reason to choose halogen is to study whether halogen bonding could play a role in the
interaction of DCB-3503 analogues and their unknown receptors. Currently halogen bonding is
becoming more and more significant in modern drug design due to its role to stabilize ligand–
protein complexes.25-28 Several triazole-modified analogues were also designed so as to increase
the volume at 3-position. It is worth noting that some triazole analogues have been already
synthesized in Dr. Baker’s lab and have been successfully applied in the identification of one
target protein of DCB-3503. The 3-propargyl-substituted analogue, which functions as the
intermediate toward the synthesis of the triazole analogues, was also screened in the model. In
addition, due to the increasing usage of fluorine in lead optimization in drug design and the
already established synthetic steps of 3-propargyloxy substituted DCB-3503 analogue, a 3-
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Table 3. The detailed results obtained from the novel CoMFA model.

(+)-(S)-tylophorine
(-)-(R)-tylophorine
(-)-antofine
(R)-cryptopleurine
(S)-cryptopleurine
DCB-3501
DCB-3506
DCB-3503
PA-5
PA-6
PA-7

NF-κB pIC50
(experimental)

CoMFA Field

) NF-κB pIC50
(predicted)

R Residue

7.387
6.499
8.137
8.854
8.854
6.502
6.492
7.060
7.959
7.921
8.000

158
166
152
160
158
160
152
160
150
148
144

7.018
6.662
8.132
8.640
8.842
6.813
6.472
7.010
8.088
7.597
8.390

0.369
0.163
0.005
0.214
0.012
0.311
0.020
0.050
0.129
0.324
0.390

Figure 10. The contour maps of the CoMFA model. (Red area: negative charge
and H-bond acceptors favored; Blue area: positive charge and H-bond donor
favored; Green area: sterically bulky groups favored; Yellow area: Sterically
bulky groups disfavored.)
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Figure 11. The basic structure and numbering system of DCB-3503 analogues.

difluorochloromethoxy substituted DCB-3503 analogue was designed and screened in the model
as well. By substituting two hydrogens with two fluorines, it was expected to affect the
conformation, hydrogen bonding and electrostatic interactions of the ligand with the proteins,
together with its metabolic stability due to the well-known ability of fluorine to block the
metabolic action of certain enzymes.29
The screening results are shown in Figure 12, and DCB-3503 was included in the screening
placed in the testing set so as to validate the model. Additionally (−)-antofine was screened
functioning as the template in the alignment of the testing set molecules to give a pIC 50 of 8.132.
According to the results, by replacing the 7-methoxy group of DCB-3503 with a chlorine or
bromine, the pIC50 increased by around 0.8, and compound 1-1 was selected as the synthetic
target due to its synthetic feasibility. However, on the basis of 1-1, if the 3-methoxy group was
modified to the propargyloxy, the activity was decreased by 0.030. It was decided to synthesize
1-3 in spite of its lower activity due to its role as the intermediate in the synthesis of the triazole
analogues, which were screened to give significantly increased activities due to their
corresponding volume increase at the 3-position from DCB-3503. In addition by substituting the
7-methoxy group with chlorine on 1-4, although not as much as what was observed on DCB-
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. Compound No.

DCB-3503

R

Predicted
NF-κB pIC50

1

2

7.007

1

2

7.832

1

2

7.835

R = OCH3 , R = OCH3

1-1 (DCB-3511)

R = OCH3 , R = Cl

1-2

R = OCH3 , R = Br
2

7.802

1-4

R = Triaz , R = OCH3

1-5
1-6
1-7
1-8
1-9
1-10
1-11
1-12

R = Triaz , R = Cl
1
2
2
R = Triaz , R = Cl
1
3
2
R = Triaz , R = Cl
1
4
2
R = Triaz , R = Cl
1
5
2
R = Triaz , R = Cl
1
6
2
R = Triaz , R = Cl
1
7
2
R = Triaz , R = Cl
1
2
R = OCF2H, R = OCH3

1-3 (DCB-3510)

Triaz1 =

Triaz5 =

1

R = HC≡C-CH2 -O, R = Cl
1

1

2

7.108

1

1

2

7.681
7.734
7.896
7.871
7.948
7.982
7.961
6.908

Triaz2 =

Triaz6 =

Triaz3 =

Triaz4 =

Triaz7 =

Figure 12. The designing and evaluation of the novel DCB-3503 analogues.
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3503, the activity increased as well. Among all the triazole-modified candidates, 1-10 with the
highest pIC50, was selected as one synthetic target. The decision was made to synthesize
compound 1-8, although which was not as promising as 1-10, the carbonyl group on the triazole
occupies more volume than a methyl, which might contribute to the activities according to the
contour maps. The last compound screened in the model was the difluoromethoxy modified
compound, which showed an even lower predicted activity than DCB-3503 possibly due to the
unwanted fluorine as the H-bonding acceptor rather than a donor at the 3-position. However, the
purpose of adding fluorine as a hydrogen mimic was to study the possible electrostatic effects
and metabolic stability that it might bring to the molecule; therefore, it was determined to keep
1-12 as a synthetic target.

2. The Synthesis of DCB-3511 (10)
The synthesis of DCB-3511 (10) was designed based on the already established route in Dr.
Baker’s lab and a recently reported synthetic route of phenanthroindolizidine alkaloids.1, 3

2.1. The Synthesis of Intermediate 1.
The synthesis of intermediate 1 was initiated by selecting anisic acid as the starting material.
The method of adding sodium hydroxide solution, followed by sodium hypochlorite solution to
an aqueous solution of anisic acid was firstly attempted, as was shown in Scheme 4.30 However,
after reaction for 1 h and work-up of the mixture, almost half of the starting material was
detected on TLC plate, leaving the mixture as a sum of a small amount of the desired product
with other impurities. To increase the yield, the reaction was allowed to stir for an extra 20 min,
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but instead of increasing the yield, more impurities including the dichlorinated product were
detected by mass spectrometry.

Scheme 4. The conditions utilized to synthesize intermediate 1 with a lower yield.

Due to the low yield and a large amount of impurities obtained from the above method, a
second attempt, which is shown in Scheme 5, was carried out utilizing Oxone® as an oxidation
agent and sodium chloride as the chlorine source.31 The reaction was started with mixing Oxone®
and a solution of anisic acid for 15 min, and the resulting mixture was then added sodium
chloride and was allowed to stir for 6 h. Upon working up, only a trace amount of anisic acid and
other impurities were indentified, making a yield of above 80% based on the integration of the
1

H NMR spectrum. The crude product was pure enough to be used in the next step without any

further purification.

Scheme 5. The conditions utilized to synthesize intermediate 1 with a higher yield.
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2.2. The Synthesis of Intermediates 2, 3 and 4.
The syntheses of intermediates 2, 3 and 4 were carried out based on the similar steps that had
been established in Dr. Baker’s lab.3
In the preparation of intermediate 2 as shown in Scheme 5, the reaction mixture was
successfully quenched by adding H 2O after cooling to room temperature. However, it was found
difficult to dissolve the resulting slurry in the aqueous K 2CO3 solution via refluxing by following
the previously established procedures. The following extraction step utilizing ether was also
attempted, and the resulting aqueous solution was further acidified with 2N HCl solution to give
only a trace amount of white precipitate, which was later confirmed to be the product. Based on
these observations, it was determined to use column chromatography (9:1 CH 2Cl2:EtOAc) to
isolate the desired product after the addition of H2O. Instead of ether, dichloromethane was used
to extract the mixture prior to running column chromatography, with the aim of increasing the
yield (a yield of 46.0% was obtained).

Scheme 6. The synthesis of intermediate 2.

Intermediate 3 was obtained in a yield of 92.5% by following the established step with no
difficulty.3 However, in the synthesis of intermediate 4, due to the electron-withdrawing nature
of the chlorine atom and the proposed mechanism of the FeCl3 -mediated ring closure reaction
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shown in Scheme 8, longer reaction times and additional FeCl3 were required.32 It was
determined that although stirring overnight with 8 equivalents of FeCl3 was sufficient to convert
most of the starting material, it was still necessary to check the reaction via TLC to assure
whether another 8 equivalents of FeCl3 were necessary after the overnight run. It was found that
the majority of intermediate 3 could be converted completely to 4 with a yield of 90.2% within 3
h after the addition of the extra FeCl3. However, it was surprising to observe that by adding the
two batches of 8 equivalents of FeCl3 all together at once and stirring overnight, there was still a
large amount of starting material left in the reaction.

Scheme 7. The synthesis of intermediates 3 and 4.

2.3. The Synthesis of Intermediate 5.
The reported reduction conditions using LiAlH 4 was firstly attempted. 1 However, for most
of the starting material, not only the ester moiety on 4 but also the chlorine attached to the
aromatic system was reduced. A similar hydrogenolysis reaction has been reported on aryl
bromides or aryl iodides, and on aryl chlorides if the reaction time is long enough. 33 Therefore, a
milder reducing agent, LiBH4, was then tested, which was shown to give a mixture of the desired
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Scheme 8. The proposed mechanism of the ring-closure step.

product and a large amount the hydrogenolysis product. Thus a third reducing agent, DIBAL-H,
was further evaluated, and upon quenching the reaction and filtering over Celite intermediate 5
was almost exclusively obtained with a yield of 87.8%. In addition the purity of the product in
the residue resulted from the concentration of the filtrate was already high enough to be utilized
directly in the next step reaction without further purification.

2.4. The Synthesis of Intermediate 6.
The brominated intermediate 6 was obtained by the addition of a bromine solution to a
solution of compound 5 as shown in Scheme 10.1 However, compared with the reported reaction
on a related phenanthroindolizidine compound, the solid obtained after filtration was a mixture
of two compounds. Therefore, further separation by column chromatography, followed by
characterization by NMR spectroscopy and mass spectrometry were carried out. According to
29

Scheme 9. The selection of the reducing agents in the synthesis of intermediate 5.

Scheme 10. The synthesis of intermediate 6.

30

the analysis results both of the two products were dibromo compounds, as they had identical
mass values and similar NMR spectra. The major difference between the two compounds was
determined to be the position of the bromine on the aromatic ring, and it has been observed
previously that the bromine was capable of being attached at different positions on the aromatic
system.34 Fortunately, a crystal of the major product was produced via the diffusion
crystallization method, and single-crystal X-ray crystallography confirmed the major compound
in the mixture was the desired product 6. However, the structure of the byproduct still remains
unknown.

Figure 13. The single-crystal X-ray crystallographic analysis of the intermediate 6.

In order to increase the yield (38.7%), different reaction conditions were tested. The first
attempt was to extend the reaction time up to 70 h. Unfortunately, by checking the reaction every
hour after the addition of bromine, the byproduct was found to be formed almost simultaneously
with the desired product. Meanwhile, the anticipated changes of the amount of the product were
not obvious after 10 h reaction, suggesting a longer reaction time was ineffective. The reaction
was also evaluated at lower temperature (-20 °C) during the addition of the bromine.
Disappointedly a similar amount of the byproduct was also formed as when it was carried out at
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0 °C. In addition, another bromination reagent, N-bromosuccinimide (NBS), was tested as well,
disappointedly giving no product.35
By failing to increase the yield under a variety of conditions, speculations about the cause of
the lower yield were made based on the proposed mechanism as shown in Scheme 11. According
to the already reported bromination reactions, all the substituents on the aromatic ring system are
electron-donating groups, which are beneficial to electrophilic attack based on the first step of
the proposed mechanism. However, if one of the substituents is replaced with an electronwithdrawing group such as chlorine, the negative effect it generated could significantly lower the
yield. In the meantime, the electron-withdrawing group at the 7-position might have an
enormous effect on the electron density of the aromatic ring, leading to a byproduct with
bromine on a different position.

Scheme 11. The mechanism proposed for the bromination step.
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2.5. The Synthesis of Intermediates 7 and 8.
For installation of the indolizidine ring system, intermediate 7 is required. The detailed
synthesis of intermediate 7 was commenced with a reported route.36 However, only a trace
amount of product was discovered when the reaction conditions were strictly followed, which
was to add N,N’-dicyclohexylcarbodiimide (DCC) after mixing diethylamine and N-Cbz-Lproline. A modified procedure was then tested by mixing DCC and N-Cbz-L -proline prior to
adding diethylamine. The mixture was allowed to stir for 10 min at 0 °C until a white precipitate
formed; afterwards, diethylamine was added, and the mixture was allowed to stir overnight at
room temperature. The switch of the addition order allowed the formation of an adequate amount
of O-acylisourea, which functions as a key intermediate in the coupling reaction. A moderate
yield of 60.45% was achieved by using this modified procedure. In order to further increase the
yield, it was attempted to heat the reaction in CH 3CN to 50 °C while stirring overnight,
unfortunately, no dramatic improvement was observed. Further increasing the temperature to
80 °C and stirring overnight also resulted in no improvement in yield.

Scheme 12. The synthesis of intermediates 7 and 8.
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With intermediate 7 in hands, the deprotection of the Cbz-group was carried out. Instead of
using HBr in acetic acid as a deprotection reagent, a more convenient and cleaner hydrogenation
method was introduced.36, 37 In this method the intermediate 7 was mixed with Pd/C in ethanol,
and the mixture was stirred under H 2 atmosphere (3 atm) for 4 h to obtain a clean product 8 with
a 98.48% yield. Only simple filtration and concentration was necessary after the reaction and no
further purification was needed. The measured specific rotation ([α]20
D = -92.2 (c = 1.1, MeOH))
matches the reported value, indicating the no occurrence of possible racemization during the
coupling reaction.36

2.6. The Synthesis of Intermediate 9 and DCB-3511 (10).
With intermediates 6 and 8 at hand, the coupling reaction with 8 was carried out with no
major difficulties to give intermediate 9 with a yield of 68.2%. The specific rotation of 9 was
measured (([α]20
D = -57.9 (c = 2.7, CH2Cl2 )) to assure that no racemization had taken place.

Scheme 13. The synthesis of intermediates 9.

To finish the synthesis, a ring closure-reaction was carried out under low temperature (78 °C), and NaBH4 was utilized to give the stereoselective product DCB-3511 (10) in a
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satisfactory yield of 89.6%, and the overall yield of the synthesis of DCB-3511 (10) is 6.77%. In
order to confirm the purity and structure of this final product, an HPLC analysis and singlecrystal X-ray analysis were performed. The stereoselectivity of NaBH 4 was confirmed by the
correct X-ray crystal structure shown in Figure 14, and the single peak in the HPLC
chromatogram shown in Figure 15 and the corresponding NMR spectra provided the information
that no observable diastereomer was generated.

Scheme 14. The synthesis of DCB-3511 (10).

3. The Synthesis of DCB-3510 (18).
The synthesis of DCB-3510 was designed based on the synthesis of DCB-3511 and the
established procedures in Dr. Baker’s lab.2, 3

3.1. The Syntheses of Intermediates 11 to 15.
The syntheses of intermediates 11 and 12 was carried out based on the previously established
procedures in Dr. Baker’s lab.3 Instead of veratraldehyde, intermediate 1 was condensed with
vanillin under aldol conditions to give the intermediate 11 in a yield of 80.0%. Then an
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Figure 14. The single-crystal X-ray crystallographic analysis of DCB-3511 (10).

Figure 15. The HPLC analysis of DCB-3511 (10).

36

esterification was carried out to give 12 in a yield of 93.2% with no major difficulty. Afterwards
intermediate 13 was synthesized with a yield of 93.3% by installing a propargyl group, which not
only constituted an important moiety in the final product, but also functioned as an HOprotecting group during the ring-closure step.2

Scheme 15. The synthesis of intermediates of 11, 12 and 13.

The same conditions used to synthesize 4 were applied directly to making intermediate 14
without modifications, and a satisfactory yield of 80.3% was obtained. An additional 8
equivalents of FeCl3 were necessary to convert all the starting material to product after 8
equivalents of FeCl3 were used initially for the overnight reaction. However, a mixture in which
a byproduct 14’ comprised up to 4.1% of the total weight was isolated and characterized by mass
spectrometry and 1H NMR spectroscopy. Interestingly, the byproduct has the same mass as the
major product, and further study by 1H NMR spectroscopy, which was shown in Figure 16,
indicated the possibility of formation of a ring-closed product at a different aromatic carbon as
indicated by the wide spin-spin splitting (9.0 Hz) at 8.90 ppm and 7.36 ppm, which suggests an
37

Scheme 16. The synthesis of intermediates of 14 and 15.

Scheme 17. The reaction generating byproduct 14’.
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ortho arrangement of the two aromatic protons at H-7 and H-8. Speculation was made that since
the southern ring could rotate along carbon A and carbon B bond, thus both carbon C and carbon
D were able to be attacked by the northern ring according to the aforementioned mechanism,
which resulted in different products. It was possible that the chlorine altered the electron density
on the southern ring, which eventually made the carbon C capable of being oxidized for the ring
closure.
Intermediate 15 could be obtained by the reduction of 14 utilizing DIBAL-H as well, and
neither the propargyl group nor the chlorine was reduced during the reaction.

3.2. The Synthesis of Intermediate 16.
The initial plan of the synthesis of intermediate 16 was to install an alkyne protecting group
before the bromination reaction due to the possibility of bromination of the alkyne. As shown in
Scheme 18, dicobalt octacarbonyl was selected as the protective group in the proposed protecting
route, and the desired product could be obtained by oxidative degradation using
Fe(NO3)3·9H2O.38 Unfortunately, no protected product was found after stirring for 36 h with 3
equivalents of dicobalt octacarbonyl; therefore, it was determined to test the direct bromination
without protection as shown in Scheme 19.
To our delight the bromine added only to the aromatic ring to give a yield of 53.6% without
interacting with the alkyne, and the attempted explanation was that the electron density of the
aromatic ring is higher than that of the alkyne, which made it the preferred place to conduct the
elctrophilic attack. A crystal of intermediate 16 was prepared, and the single-crystal X-ray
crystallographic analysis was performed, providing the result seen in Figure 17.
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Scheme 18. The initial synthetic route to intermediate 16.
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Figure 16. The 1H NMR (300 MHz, CDCl3) spectrum of the byproduct
14’. (First spectrum: Overall view; Second spectrum: Enlarged view of
the aromatic protons).
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Figure 16. Cont’d.

42

Figure 16. Cont’d.
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Scheme 19. The modified synthesis of intermediate 16.

Figure 17. The single-crystal X-ray crystallographic analysis of intermediate 16.
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3.3. The Synthesis of Intermediate 17.
With intermediate 16 in hand, the synthesis of 17 was carried out following the same
procedure used in preparing intermediate 9. However, in order to avoid the possible propargyl
Claisen rearrangement which would yield the allene as shown in Scheme 20, the reaction
temperature was lowered from reflux (153 °C) to 70 °C. These conditions were selected as all
Claisen rearrangement reactions are said to happen above 100 °C if uncatalyzed.39 Under these
conditions the desired product was obtained with a yield of close to 90%. Additionally, a test of
this reaction under reflux conditions was attempted, and several byproducts were obtained with
no desired product detected. The 1H NMR spectrum of the major byproducts was believed to be
the rearranged product based on the disappearance of the terminal alkyne triplet peak in the highfield region and the appearance of a similar peak at 7.06 ppm representing the internal allene
proton, as could be seen in Figure 18. In addition, the m/z of the [M+H]+ peak of this byproduct
was obtained as 587.13095 by mass spectrometry, which was almost identical as the one of 17 as
587.13118.

Scheme 20. The proposed formation of the unexpected product in the synthesis of
intermediate 17.
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Figure 18. The 1H NMR (300 MHz, CDCl3) spectrum of the unexpected product
formed in the synthesis of intermediate 17. (First spectrum: Overall view; Last two
spectra: Detailed view.)
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Figure 18. Cont’d.
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Figure 18. Cont’d.
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Scheme 21. The synthesis of intermediate 17.

3.4. The Synthesis of DCB-3510 (18).
The synthesis of DCB-3510 was carried out utilizing conditions similar to those used in
preparing 10. However, one additional equivalent of n-BuLi was used to compensate the possible
consumption by the terminal alkyne. The final product was obtained with no major difficulty,
and a yield of 94.1% was achieved without the observation of any possible side reactions caused
by the acetylide. The overall yield of the synthesis of DCB-3510 (18) is 20.5%. It was also
confirmed by HPLC and NMR spectroscopy that the major product was optically pure as shown
in Figure 19, as no observable diastereomer was formed.

Scheme 22. The synthesis of DCB-3510 (18).
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Figure 19. The HPLC analysis of DCB-3510 (18).

4. The Synthesis of DCB-3512 (20a).
4.1. The Selection of the Synthetic Targets.
Two triazole-modified analogues (20 and 22) shown in Figure 20 were selected as the
synthetic targets from the aforementioned triazole analogues designed by the CoMFA model
based on both the CoMFA prediction results, which was to increase the volume and decrease the
electron density at the 3-position, and the assessment of the feasibility of synthesizing these
molecules. The selected analogues ranged from the simple acyl triazole to a more complex
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aromatic acyl-substituted triazole group. However, before carrying out the synthesis of 22, the
synthesis of compound 21 was firstly attempted.

Figure 20. The structures of compounds 20, 21 and 22.

4.2. The Attempted Synthesis of Intermediates 21 and 22.
The first synthesis was carried out on acetyl azide by refluxing acetyl chloride and sodium
azide in a water–THF solvent system.40 However, only a trace amount of product was detected
by mass spectrometry, and due to the volatility of the acetyl chloride and explosive potential of
this small molecular weight organic azide, a decision was made to abandon the attempted
synthesis of 21.

Scheme 23. The proposed synthesis of acetyl azide.
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The focus was then switched to the synthesis of 2-methoxybenzoyl azide by introducing tBuOCl as an oxidative reagent and NaN 3 as the azide source.41 The t-BuOCl prepared in situ was
stirred with NaN3 for 24 h, and column chromatography was performed to isolate the pure
organic azide product.42 A longer reaction time aimed at increasing the yield was tried; however
instead of increasing the yield, a byproduct from the Curtius rearrangement, 2-methoxyaniline,
was detected. Another method to synthesize 2-methoxybenzoyl azide starting from 2methoxybenzoic acid using cyanuric chloride was attempted as well; unfortunately, it gave an
unsatisfactory result.43 After obtaining 2-methoxybenzoyl azide, although in an unsatisfactory
yield, the copper(I)-catalyzed alkyne–azide cycloaddition (CuAAC) was carried out on DCB3510 and 2-methoxybenzoyl azide using a more affordable salt, CuSO 4·5H2 O, as the catalyst and
sodium ascorbate as the reducing agent.44 However, only starting material (DCB-3510) and the
3-hydroxy DCB-3510 analogue, which resulted from ripping off of the propargyl group, were
recovered from the reaction mixture. By suspecting the catalytic ability of the combination of
Cu(II) salt and sodium ascorbate, Cu(I) salt (CuI) was introduced directly. 45 Again the starting
material, DCB-3510, was recovered from the reaction mixture with no sign of the cycloaddition
product.

Scheme 24. The attempted synthesis of 2-methoxybenzoyl azide.
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By failing to obtain either compound 21 or 22, the synthetic target was switched to making
solely alkyl triazole analogues since suspicion was falling on the feasibility of conducting
CuAAC on an acyl azide largely due to its unreactive nature. Therefore, the synthesis of
compound 20 was attempted.

Scheme 25. The attempted synthesis of compound 22 via CuAAC (Top: indirect
introduction of Cu(I) catalyst; Bottom: direct introduction of Cu(I) catalyst).

The synthesis of N-aralkyl-substituted 20 (Figure 20) was commenced with the preparation
of 1-(azidomethyl)-3-nitrobenzene (19) based on the reported procedures.46 However, only a
moderate yield of 66.67% of 19 was achieved by analyzing the 1H NMR integration of the
spectrum, and a mixture of 3-nitrobenzyl bromide and 19 was obtained. Due to the difficulty of
separating the resulting mixture containing two compounds with extremely similar polarities,
together with 19’s explosive nature and its unstable properties on silica gel, it was determined to
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utilize the crude product directly in the synthesis of 20. The CuAAC reaction was carried out
using Cu(I) salt (CuI) directly as the catalyst, and the major product was isolated.45 The purity of
the product was determined by HPLC as shown in Figure 21.

Scheme 26. The synthesis of intermediate 19.

Fortunately, the CuAAC reaction was successfully performed; however, what was interesting
was the tertiary amine in the indolizidine moiety reacted with the 3-nitrobenzyl bromide in the
crude product to yield a quaternary ammonium salt 20a (DCB-3512) shown in Scheme 27 with a
yield of 41.3%, and the majority of the rest of the impurities was confirmed to be the
corresponding quaternary ammonium salt of DCB-3510 (i.e., the salt of 18). In the beginning a
salt was detected by mass spectrometry with a bromide as the negative ion and a molecule
constituted of the target molecule and an extra 3-nitrobenzyl group as the positive ion. Although
it was concluded the material was a single molecule by HPLC and mass spectrometric analysis, a
DOSY NMR experiment was performed to further confirm that it was a single molecule. The
speculation was then made that the extra benzyl CH2 group was associated with on either the 3nitrogen in the triazole or on the nitrogen in the indolizidine to make a 1,2,3-triazolium ion or a
quaternary ammonium ion. Further NMR spectroscopy studies helped to draw the definitive
conclusion that the extra 3-nitrobenzyl group was on the indolizidine nitrogen. The 1H and 13C
NMR assignments of compound 20a were made based on the analysis of COSY, HSQC, HMBC,

54

Scheme 27. The synthesis of DCB-3512 (20a).

Figure 21. The HPLC analysis of DCB-3512 (20a).
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H2BC, NOESY and 1H-15N HMBC spectra as shown in Figure 22.
The positions of two identical 3-nitrobenzyl groups A and B were made mostly based on
HMBC and NOESY spectra. In the HMBC spectrum, the hydrogens of one of the two CH2
groups with chemical shifts of 4.34 and 4.85 ppm could not only correlate to three aromatic
carbons, but also to two aliphatic carbons with chemical shifts of 60.81 and 57.48 ppm,
indicating its proximity to the indolizidine moiety. Therefore these two hydrogens were on the B
3-nitrobenzyl group. In the NOESY spectrum, the CH2 group with a chemical shift of 5.72 ppm
correlated with the triazole hydrogen (8.10 ppm), suggesting its belonging to the A 3-nitrobenzyl
group that was proximate to the triazole moiety. In addition, one of the hydrogens of CH 2 in
group B at the chemical shift of 4.34 ppm was also close to two hydrogens with chemical shifts
of 2.69 and 2.54 ppm; meanwhile, the other hydrogen in the CH2 group with a chemical shift of
4.85 was close to the hydrogen in the hydroxyl group at 6.30 ppm, indicating the possible
position of the flexible 3-nitrobenzyl group as behind the indolizidine ring as can be shown in 3D
structure constructed in the SYBYL program in Figure 23.
The unexpected compound 20a was formed mainly due to the usage of the crude mixture of
3-nitrobenzyl azide and 3-nitrobenzyl bromide. Since a large excess crude 3-nitrobenzyl azide
was used in the CuAAC reaction to assure the maximum conversion of DCB-3510, it was
inevitable to introduce almost the same excess amount of 3-nitrobenyl bromide into the reaction
system, which reacted with the tertiary amine to give the ammonium salt. Although the resulting
product was not the desired compound 20, it might provide a promising candidate according to
the CoMFA contour map prediction. Firstly, as can be seen in the contour map in Figure 24,
there was a large red area occupying the space that the 3-nitrobenzyl group B fell into, meaning
the negatively charged groups and H-bond acceptors were favored. Fortunately, the nitro group
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Figure 22. The 1H and 13C NMR chemical shift assignments of DCB-3512 (20a).

Figure 23. The energy-minimized 3D structure of DCB-3512 (20a).

57

in 3-nitrobenzyl group B was able to provide extra negatively charged groups and H-bond
acceptors, making compound 20a a possible promising candidate. Compound 20a was also
placed into the CoMFA model to predict its activity against NF-κB pathway, and a moderate
result of 7.399 (pIC50) was obtained. However, due to the difficulties of constructing the salt
molecule and assigning the corresponding charges in the SYBYL program, and the uncertain
positions of the flexible 3-nitrobenzyl group B, it is not feasible to accurately predict the activity
of compound 20a. Besides the CoMFA predictions, the alteration of the solubility of this
analogue via its transformation into a salt also rendered 20a a potential active candidate. One
major aspect that was detrimental to the activities of tylophorine analogues was their poor
solubility in either organic solvents or water; however by modifying to the corresponding salt the
solubility in water might increase dramatically, which could ultimately improve the biological
activity.

Figure 24. The electrostatic contour map in the novel CoMFA model. (Red area:
negative charge and H-bond acceptors favored; Blue area: positive charge and Hbond donor favored.)
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5. The Attempted Synthesis of Compound 28 (Scheme 32).
In the synthesis of compound 28, the chlorodifluoromethoxy group was determined to be
installed at an early stage as a protective group, aiming at avoiding the extra steps and the harsh
conditions of protecting and deprotecting of the hydroxyl group at the late stage, where the
unstable phenanthroindolizidine alkaloid might be easily decomposed.

5.1. The Synthesis of Intermediate 23.

Scheme 28. The synthesis of intermediate 23.

The synthesis of intermediate 23 began with (E)-methyl 2-(3,4-dimethoxyphenyl)-3-(4hydroxy-3-methoxyphenyl)acrylate, which was prepared based on the procedures already
established in Dr. Baker’s lab.3 Sodium chlorodifluoroacetate, which functioned as a
difluorocarbene precursor, was utilized under thermolysis conditions to give the difluoromethoxy
group on the north ring with a yield of 34.4%.47, 48 The difluoromethoxy 1H and 13C NMR peaks
could be found in the spectra shown below, proving the successful installation of the
difluoromethoxy group.
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Figure 25. The 1H NMR (500 MHz, CDCl3) spectrum (first specturm) and 13C NMR
(125 MHz, CDCl3) spectrum (second spectrum) of intermediate 23 with the enlarged
view of difluoromethoxy peaks.
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Difluoromethoxy peaks

Figure 25. Cont’d.
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Difluoromethoxy peaks

Figure 25. Cont’d.
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5.2. The Synthesis of Intermediates 24 and 25.
The syntheses of intermediates 24 (a yield of 94.1%) and 25 (a yield of 98.1%) were carried
out by following the same conditions used in the previous synthesis of DCB analogues. No major
difficulty was encountered during the syntheses of these compounds; however, additional FeCl3
was necessary in the synthesis of 24.

Scheme 29. The synthesis of intermediate 24 and 25.

5.3. The Synthesis of Intermediate 26.
In the synthesis of 26 the same conditions used in preparing intermediate 6 were used, and a
mixture of was obtained as expected. The major product (a yield of 60.6%) was isolated by
column chromatography and analyzed by mass spectrometry and 1H NMR spectroscopy, which
confirmed the whole structure of the compound except the position of the bromine on the
aromatic system. Unfortunately attempts to crystallize this compound for a better elucidation of
its structure failed; therefore 1D NOESY NMR experiments were conducted on the Varian
VNMRS 600 MHz spectrometer.
The 1H NMR and four 1D NOESY NMR spectra are shown in Figures 27 and 28, and all five
possible positions where the bromine might be located are labeled in Figure 26. According to the
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Scheme 30. The synthesis of intermediate 26.

Figure 26. The five positions assigned on intermediate 26.

1D NOESY spectra, there is only one aromatic H (7.49 ppm) that was close enough to the
bromomethyl H (5.26 ppm), suggesting the other bromine had to be on either 4- or 5-position.
However, if the bromine were on the 4-position, there should be two pairs of aromatic Hs (1- and
-5 or 2- and 3-) that are close enough to show a NOESY interaction. In the spectra shown below
only one pair of aromatic Hs (8.23, 7.78 ppm) could be found, indicating the position of the
bromine was not on 4-position. Therefore, the bromine had to be on 5-position, which made the
Hs on 2- and 3-position close to each other. The assignment of each H could also be made
according to the spectra. The H (8.23 ppm) was the one at 2-position since it was only close to
one aromatic H and not close to the methoxy Hs. The H with a chemical shift of 7.93 ppm
occupied the 1-position due to its proximity to the methoxy Hs and the long distance to the
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bromomethyl Hs. The H (7.78 ppm) was the one at 3-position because it was close to both
methoxy Hs and one aromatic H. The last H (7.49 ppm) should be the H on the 4-position based
on its close distance to the methoxy Hs and bromomethyl Hs.

5.4. The Synthesis of Intermediates 27 and 28.
With intermediate 26 in hand and its structure confirmed, the synthesis of 27 was performed
by the same procedure used in preparing intermediate 17 (Scheme 21) to give a yield of 83.1%.
For the synthesis of the target product 28, the chemistry outlined in Scheme 22 for the
synthesis of 18 was followed. However, in the case of 28, a mixture was obtained after the
NaBH4 reduction, and no desired product was detected by either mass spectrometry or NMR
spectroscopy. The m/z of the [M+H] + peak of one compound in the mixture was found to be
467.25479 by mass spectrometry, suggesting a structure shown in Figure 29. Speculation was
that the ring-closure step was the failed step, and the reducing agent removed the difluoromethyl
group. Therefore, a test was conducted to confirm the above speculation by running mass
spectrometry after quenching the active aryl carbanion with CD 3OD before the addition of
NaBH4. As expected, an m/z of the [M+H]+ peak at 518.28839 was found in the mixture, which
indicated the proposed deuterated structure shown in Figure 30. Disappointedly the desired
[M+H]+ peak corresponding to the structure shown in Figure 31 was not found. Although the
exact cause of the failure of the ring closure is not clear, speculation is that the difluoromethyl
group, which has a strong electron-withdrawing effect, might stabilize the aryl carbanion which
does form as shown by the deuteration experiment through the aromatic system and lead to its
resistance of attacking the amide carbonyl group.
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Figure 27. 1H NMR (600 MHz, CDCl3) spectrum of intermediate 26.
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Figure 28. 1D NOESY NMR (600 MHz, CDCl3) spectra of intermediate 26.
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Figure 28. Cont’d.
.
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Figure 28. Cont’d.
.
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Figure 28. Cont’d.
.
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Figure 28. Cont’d.
.
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Scheme 31. The synthesis of intermediate 27.

Figure 29. The unexpected product in the attempted synthesis of compound 28.

Figure 30. The deuterated intermediate in the route for the synthesis of compound 28.
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Figure 31. The ring-closed intermediate expected in the attempted synthesis of
compound 28.

Scheme 32. The attempted synthesis of compound 28.
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6. The Biological Studies of DCB-3510, DCB-3511 and DCB-3512
6.1. The Results of the Biological Studies.
The biological activities of the newly synthesized compounds DCB-3510, DCB-3511 and
DCB-3512 were studied with DCB-3503 as a reference in Dr. Cheng’s lab at Yale University
School of Medicine. The cytotoxicity of these compounds against HepG2, Huh7 and HLN liver
cancer cell lines and the anti-hepatitis C virus (HCV) activities were determined and the results
are shown in Table 4.

Table 4. The biological activities of DCB-3510, DCB-3511, and DCB-3512.

Cytotoxicity IC50 (µm)

DCB-3503
DCB-3510
DCB-3511
DCB-3512

HepG2
0.3 ± 0.06
5.2 ± 0.9
9.5 ± 0.2
24 ± 2.9

Huh7
0.56 ± 0.3
2.6 ± 0.9
1.7 ± 0.8
8.6 ± 1.8

HLN
0.45 ± 0.1
1.7 ± 0.65
2.2 ± 0.6
14 ± 2.1

Anti-HCV Activity ID50
(µm)
HCV
0.03 ± 0.004
2.7 ± 0.6
1.6 ± 0.45
9.1 ± 1.9

6.2. The Analysis of the Inconsistencies of the Predictive and the
Experimental Data.
To our surprise, although these three novel compounds were still active according to the
results, they were not as potent as DCB-3503 either for their cytotoxicity against the cancer cell
lines or on the anti-HCV activity. Meanwhile by increasing the substituent volume at the 3-
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position, the activities decreased as can be seen for DCB-3510 and DCB-3512, which was not
consistent with the predictions of the CoMFA model that was developed for the NF-κB
pathway—not whole-cell cytotoxicity. What is interesting is that the nitrogen of the indolizidine
moiety might not function as an important H-bond acceptor due to the still active biological data
of DCB-3512 as an ammonium salt. However, if one takes the difference between the data used
to construct the CoMFA model, which was the IC50 against NF-κB pathway, and the testing
results data which was the IC50 or ID50 against whole cells into consideration, it is possible that
these data are not suitable to evaluate the accurate prediction ability of CoMFA. Although these
analogues are believed to affect the NF-κB pathway, other pathways cannot be ruled out.
Additionally even if the NF-κB pathway was the only pathway being affected, it was still
possible multiple proteins in this pathway could be the targets, not to mention the possibility of
the existence of multiple binding sites on one protein.
Although it was difficult to give direct proof of the above analysis, one screening result from
another independent group might shed light on it. In the study conduct by Wang’s group, it was
found the same modifications would bring the opposite effect on tylophorine and DCB-3503.
The cytotoxicity against the A549 cell line of several tylophorine analogues are shown in Figure
32.17 It is obvious that if there was no hydroxyl group at 14-position, the 7-methoxy compounds
were less potent than the 7-hydrogen one. However, by adding a hydroxyl group at the 14position rendering the S configuration, the 7-methoxy compound was more active than the 7hydrogen one. It is possible that by adding a hydroxyl group the total mechanism of the resulting
analogue is changed, and the previous study has shown that the addition of a 14-hydroxyl group
at least changed the pharmacokinetics.7 Although the molecules used to construct the CoMFA
model in the training set were believed to function by way of the NF-κB pathway, the 14-
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hydroxyl ones and 14-hydrogen ones might bind to different proteins or different sites on the
same protein, which eventually made the CoMFA model not that predictable.
The prediction made by the CoMFA that by decreasing the substituent volume at the 7position the activity increases came from merely the molecules without 14-hydroxyl groups due
to a lack of available experimental data, and this lack of experimental data for a larger variety of
molecules, together with their complicated and varied mechanisms, made the model not as
predictable as desired. Additionally the non-rigid and flexible triazole arm at the 3-position made
it more difficult to accurately predict the activity due to the multiple positions of the arm that
could be placed in the calculated CoMFA field. Based on the above analysis, although the
ligand-based approach utilizing CoMFA model might not be the ideal tool for designing novel
tylophorine analogues due to the lack of diversity in the molecules in the training set, and the
lack of corresponding data and the uncertain mechanisms that occur with structural changes, it
still shed light on the complexity and diversity of the possible anti-cancer mechanisms of DCB3503.
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Compound No.

A549 GI50 (µm)

A
B
C
D
E
F
G
H
I
J

0.70
0.30
0.50
0.01
0.06
<0.001
0.67
>10
0.40
1.00

A R = OCH3

C R = OCH3

B R=H

D R=H

E R = OCH3

G R = OCH3

I R = OCH3

F R=H

H R=H

J R=H

Figure 32. The analysis of the inconsistencies of the experimental and
predictive biological activities of the novel DCB-3503 analogues.
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V. EXPERIMENTAL
The analytical TLC was performed on 0.2-mm aluminum-backed plates (Sorbent
Technologies, Norcross, GA), and the detection was carried out by 254 nm UV light and/or
dipping–heating with p-anisaldehyde–sulfuric acid dip.49 Column chromatography was run by
utilizing silica gel, 63–200 mesh (Sorbent Technologies, Norcross, GA). 1H and 13C NMR
spectra were acquired at 25 °C on a Varian VNMRS 500 spectrometer at 500 MHz and 125 MHz,
respectively, or a Varian VNMRS 600 spectrometer at 600 MHz and 150 MHz, respectively.
Chemical shifts are reported in δ (ppm) units relative to the signal of CDCl3, THF-d8 or CD3CN
for 1H or 13C. All 2D NMR spectra were obtained on Varian VNMRS 500 or Varian VNMRS
600 instruments. High-resolution mass spectra were acquired on a JEOL AccuTOF-DART
spectrometer with an ESI source or on a Q-Star TOF spectrometer with an ESI source.

1. The Construction of the Novel CoMFA Model.
The inhibitory activities against NF-κB pathway of a series of tylophorine analogues
obtained from Dr. Cheng’s lab, all of which were believed to function through the same
mechanism, were selected as the training set of this model.11, 14 The IC50 data in M-1 scale were
then converted to pIC50 values before the application in the model. The two enantiomers of
cryptopleurine were considered as equally effective as they were tested as a racemic mixture.
The model was constructed using the SYBYL-X 2.1 molecular modeling program (Tripos
International, St. Louis, MO). All the molecular structures were constructed by the Sketcher in
SYBYL-X 2.1, and their energies were minimized in MMFF94s force field after the assignment
of MMFF94 charges.
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All the prepared molecules were then superimposed on a common core shown in Figure 8
with (−)-antofine as the template, which was selected due to its second highest pIC 50 that might
represent the most bioactive conformation of this series of analogues. The reason why
cryptopleurine was not chosen was because its IC 50 was obtained from a racemic mixture,
making it impossible to differentiate which isomer possesses a higher value.
The already aligned molecules were then placed in a 3D grid with a spacing of 2 Å, and the
Tripos standard field was used to calculate the steric (Lennard-Jones potential) and electrostatic
(Coulomb potential) energies by introducing an sp3 carbon with a + 1 charge as the probe. The
truncation cutoffs of the steric and electrostatic fields were both 30.0 kcal/mol. A partial least
square (PLS) analysis was then carried out using the default setting in SYBYL-X 2.0. A leaveone-out (LOO) cross-validation was firstly calculated to give the q2 and the optimal number of
components, the latter of which provided the highest q2 and lowest standard error. The optimal
number of components was then used in non-cross-validation to give conventional correlation
coefficient r2.
After completion of the model the contour maps could be examined, and the correlated
modifications could be made. All the novel molecules designed from the contour maps were also
built in the Sketcher in SYBYL-X.2.1, and their corresponding energies were minimized in the
MMFF94s force field after the assignment of the MMFF94 charges. The alignment of the testing
set molecules were carried out using the same common core; however, (−)-antofine was added to
the testing set as the alignment template to maintain the consistency.
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2. The Synthesis of the Novel DCB-3503 Analogues.
Preparation of 2-(3-chloro-4-methoxyphenyl)acetic acid (1)

A solution of 2-(4-methoxyphenyl)acetic acid (0.850 g, 5.12 mmol) in 8.5 mL acetone was added
Oxone® (3.15 g, 10.2 mmol), and the resulting suspension was stirred for 15 min at room
temperature. Then an aqueous solution of NaCl (1.19 g, 20.4 mmol, in 8.5 mL H2O) was added
dropwise to the suspension, and the reaction mixture was stirred for 6 h at room temperature.
Afterwards the solvent was removed by rotary evaporation, and the residue was diluted with H2O
(43 mL) and extracted by ethyl acetate (3 × 30 mL). The combined organic layer was then dried
with anhyd MgSO4 and concentrated in vacuo to yield crude 2-(3-chloro-4methoxyphenyl)acetic acid (1, a yield of >80.0% by 1H NMR integration) as a yellowish red
solid. 1H NMR (500 MHz, CDCl3) δ 7.27 (d, J = 2.5 Hz, 1H), 7.10 (dd, J = 8.5, 2.0 Hz, 1H),
6.85 (d, J = 8.5 Hz, 1H), 3.84 (s, 1H), 3.54 (s, 1H). 13 C NMR (125 MHz, CDCl3) δ 39.71, 56.11,
112.14, 122.35, 126.22, 128.78, 131.07, 154.26, 177.94. HRDARTMS: Calcd for C9H9ClO3 m/z
200.02402; [M−H]+ m/z 199.01547 (calcd 199.01620).

80

Preparation of (E)-2-(3-chloro-4-methoxyphenyl)-3-(3,4-dimethoxyphenyl)acrylic acid (2)

To a suspension of 2-(3-chloro-4-methoxyphenyl)acetic acid (1, 1.50 g, 7.50 mmol) and 3,4dimethoxybenzaldehyde (1.25 g, 7.50 mmol) in acetic anhydride (4.14 mL, 43.7 mmol),
triethylamine (2.63 mL, 18.7 mmol) was added, and the mixture was stirred at 100 °C for 24 h.
Afterwards the reaction was allowed to cool to room temperature and H2O (3.75 mL) was slowly
added, then the mixture was cooled to room temperature again and extracted with CH2 Cl2 (3 ×
15 mL). The organic layer was then dried over MgSO 4 and concentrated in vacuo. The residue
was further purified by column chromatography (9:1 CH 2Cl2:EtOAc) to give (E)-2-(3-chloro-4methoxyphenyl)-3-(3,4-dimethoxyphenyl)acrylic acid (2, 1.20 g, 3.45 mmol, 46.0% yield) as a
light-yellow precipitate. 1H NMR (500 MHz, CDCl3) δ 7.88 (s, 1H), 7.33 (d, J = 2.0 Hz, 1H),
7.14 (dd, J = 8.5, 2.0 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 6.85 (dd, J = 8.5, 2.0 Hz, 1H), 6.74 (d, J
= 8.5 Hz, 1H), 6.55 (d, J = 2.0 Hz, 1H), 3.92 (s, 3H), 3.86 (s, 3H), 3.51 (s, 3H). 13C NMR (125
MHz, CDCl3) δ 55.24, 55.83, 56.22, 110.62, 112.27, 112.60, 122.79, 125.86, 126.81, 127.29,
128.86, 129.54, 131.81, 142.92, 148.34, 150.59, 154.68, 172.69. HRDARTMS: Calcd for
C18H17ClO5 m/z 348.07645; [M+H]+ m/z 349.08376 (calcd 349.08428).
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Preparation of (E)-methyl 2-(3-chloro-4-methoxyphenyl)-3-(3,4-dimethoxyphenyl)acrylate
(3)

(E)-2-(3-chloro-4-methoxyphenyl)-3-(3,4-dimethoxyphenyl)acrylic acid (2, 4.66 g, 13.4 mmol)
was dissolved in dry methanol (230 mL), and to this solution concd H2 SO4 (4.60 mL) was added
and the resulting solution was stirred for 12 h at 65 °C. Afterwards the reaction mixture was
concentrated via rotary evaporation, and the slurry was purified by column chromatography (9:1
CH2Cl2:EtOAc) to give (E)-methyl 2-(3-chloro-4-methoxyphenyl)-3-(3,4dimethoxyphenyl)acrylate (3, 4.47 g, 12.4 mmol, 92.5% yield) as a pale-yellow solid. 1H NMR
(500 MHz, CDCl3 ) δ 7.77 (s, 1H), 7.29 (d, J = 2.0 Hz, 1H), 7.10 (dd, J = 8.5, 2.5 Hz, 1H), 6.95
(d, J = 8.5 Hz, 1H), 6.80 (dd, J = 8.5, 2.0 Hz, 1H), 6.71 (d, J = 8.5 Hz, 1H), 6.50 (d, J = 2.5 Hz,
1H), 3.90 (s, 3H), 3.83 (s, 3H), 3.77 (s, 3H), 3.49 (s, 3H). 13C NMR (125 MHz, CDCl3 ) δ 52.32,
55.21, 55.79, 56.19, 110.61, 112.25, 112.47, 122.68, 125.37, 127.08, 128.26, 129.45, 129.47,
131.73, 140.94, 148.27, 150.16, 154.53, 168.16. HRDARTMS: Calcd for C19H19ClO5 m/z
362.09210; [M+H]+ m/z 363.10008 (calcd 363.09993).
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Preparation of methyl 7-chloro-2,3,6-trimethoxyphenanthrene-9-carboxylate (4)

A solution of (E)-methyl 2-(3-chloro-4-methoxyphenyl)-3-(3,4-dimethoxyphenyl)acrylate (3,
4.05 g, 11.2 mmol) in CH 2Cl2 (250 mL) was cooled to -10 °C, and to this solution a freshly
prepared solution of FeCl3 (13.0 g, 80.8 mmol) in EtOAc (250 mL) was added dropwise, and the
resulting mixture was stirred overnight at room temperature. Then the reaction was checked by
TLC. If compound 3 could still be found, then an equal amount of FeCl3 (13.0 g, 80.8 mmol) in
EtOAc (250 mL) was added with stirring until all the starting material was consumed. Then H2O
(272 mL) was added, and the reaction mixture was stirred for 3 h at room temperature.
Afterwards the mixture was extracted by CH 2Cl2 (3 × 200 mL), and the combined organic layer
was dried with anhyd MgSO4 and concentrated via rotary evaporator. The pure methyl 7-chloro2,3,6-trimethoxyphenanthrene-9-carboxylate (4, 3.62 g, 10.1 mmol, 90.2% yield) could then be
obtained as a white solid by column chromatography (9:1 CH2Cl2:hexanes). 1H NMR (500 MHz
CDCl3) δ 9.06 (s, 1H), 8.27 (s, 1H), 7.70 (s, 1H), 7.67 (s, 1H), 7.20 (s, 1H), 4.11 (s, 3H), 4.09 (s,
3H), 4.03 (s, 3H), 4.00 (s, 3H). 13 C NMR (125 MHz, CDCl3) δ 52.13, 55.97, 56.06, 56.10,
102.80, 103.02, 109.29, 122.39, 123.45, 123.59, 125.45, 126.36, 128.05, 129.96, 130.55, 149.78,
151.20, 153.30, 167.61. HRDARTMS: Calcd for C19 H17ClO5 m/z 360.07645; [M+H] + m/z
361.08364 (calcd 361.08428).
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Preparation of (7-chloro-2,3,6-trimethoxyphenanthren-9-yl)methanol (5)

Methyl 7-chloro-2,3,6-trimethoxyphenanthrene-9-carboxylate (4, 2.00 g, 5.56 mmol) was
dissolved in THF (150 mL), and the solution was maintained under N 2 atmosphere in an ice bath.
To this solution a solution of 1.0 M DIBAL-H in hexanes (22.4 mL, 22.4 mmol) was then added
dropwise, and the reaction mixture was allowed to stir overnight at room temperature.
Afterwards the reaction was again cooled in an ice bath and Na2 SO4·10H2O was carefully added
until the formation of bubbles came to a stop. The resulting mixture was then filtered through
Celite and concentrated by rotary evaporation to give (7-chloro-2,3,6-trimethoxyphenanthren-9yl)methanol (5, 1.62 g, 4.88 mmol, 87.8% yield) as a white solid. 1H NMR (500 MHz, CDCl3) δ
8.14 (s, 1H), 7.80 (s, 1H), 7.74 (s, 1H), 7.55 (s, 1H), 7.16 (s, 1H), 5.06 (s, 2H), 4.11 (s, 3H), 4.10
(s, 3H), 4.02 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 55.92, 56.11, 56.26, 63.99, 103.15, 103.72,
108.48, 122.70, 123.98, 124.11, 124.50, 125.93, 126.93, 130.05, 131.89, 149.44, 149.70, 153.31.
HRDARTMS: Calcd for C18 H17ClO4 m/z 332.08154; [M]+ m/z 332.08076 (calcd 332.08154).
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Preparation of 9-bromo-10-(bromomethyl)-2-chloro-3,6,7-trimethoxyphenanthrene (6)

To a solution of 7-chloro-2,3,6-trimethoxyphenanthren-9-yl)methanol (5, 2.00 g, 6.02 mmol) in
CH2Cl2 (50 mL) at 0 °C was added a solution of Br 2 (1.00 g, 6.26 mmol) in CH2Cl2 (10 mL).
The resulting reaction mixture was then stirred overnight at room temperature. Afterward the
solvent was removed by rotary evaporation, and column chromatography (6:4 CH2Cl2:hexanes
followed by pure CH2 Cl2) was performed to give bromo-10-(bromomethyl)-2-chloro-3,6,7trimethoxyphenanthrene (6, 1.10 g, 2.33 mmol, 38.7% yield) as a white solid. 1 H NMR (500
MHz, CDCl3) δ 8.15 (s, 1H), 7.83 (s, 1H), 7.81 (s, 1H), 7.77 (s, 1H), 5.20 (s, 2H), 4.14 (s, 3H),
4.13 (s, 3H), 4.09 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 32.28, 56.07, 56.20, 56.33, 103.10,
103.68, 109.67, 123.76, 123.80, 124.26, 125.12, 126.01, 126.32, 128.67, 129.33, 150.40, 150.43,
153.87. HRDARTMS: Calcd for C18H15Br 2ClO3 m/z 471.90765; [M+H]+ m/z 472.91725 (calcd
472.91547).
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Preparation of (S)-benzyl 2-(diethylcarbamoyl)pyrrolidine-1-carboxylate (7)

To an ice-cold solution of (S)-1-((benzyloxy)carbonyl)pyrrolidine-2-carboxylic acid (1.00 g, 4.02
mmol) in CH2Cl2 (8.0 mL), a solution of N,N'-dicyclohexylcarbodiimide (0.880 g, 4.27 mmol) in
CH2Cl2 (8.0 mL) was added dropwise. After the formation of a white precipitate, a solution of
diethylamine (0.420 mL, 4.03 mmol) in CH2Cl2 (8.0 mL) was added dropwise, and the resulting
mixture was allowed to stir overnight at room temperature. Afterwards the reaction mixture was
filtered, and the resulting filtrate was further purified by column chromatography (4:6
EtOAc:hexanes) to give (S)-benzyl 2-(diethylcarbamoyl)pyrrolidine-1-carboxylate (7, 0.740 g,
1
2.43 mmol, 60.4% yield) as a colorless liquid. [α]20
D = −30.4 (c = 1.2, MeOH). H NMR (500

MHz, CDCl3) δ 7.10–6.99 (m, 5H), 4.83 (dd, J = 90.7, 12.2 Hz, 1H), 4.82 (t, J = 12.0 Hz, 1H),
4.32 (ddd, J = 61.7, 8.2, 3.5 Hz, 1H), 3.45–3.38 (m, 1H), 3.33–3.09 (m, 3H), 3.01–2.86 (m, 2H),
1.97–1.75 (m, 2H), 1.63–1.53 (m, 2H), 0.94 (dt, J = 73.7, 7.2 Hz, 3H), 0.72 (dt, J = 33.0, 7.0 Hz,
3H). 13C NMR (125 MHz, CDCl3) δ 12.69, 13.95, 23.25, 29.91, 41.32, 46.53, 56.17, 66.35,
127.31, 127.52, 127.67, 127.92, 128.03, 128.14, 136.37, 153.92, 171.35. HRDARTMS: Calcd
for C17H24N2O3 m/z 304.17869; [M+H]+ m/z 305.18648 (calcd 305.18652).
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Preparation of (S)-N,N-diethylpyrrolidine-2-carboxamide (8)

Pd/C (0.06 g, 10% Pd) was added to a solution of (S)-benzyl 2-(diethylcarbamoyl)pyrrolidine-1carboxylate (7, 0.600 g, 1.97 mmol) in C2H5 OH (60 mL), and the resulting mixture was stirred
under H2 atmosphere for 4 h. Afterwards the mixture was filtered, and the solvent in the filtrate
was removed via rotary evaporation to give (S)-N,N-diethylpyrrolidine-2-carboxamide (8, 0.330
1
g, 1.94 mmol, 98.5% yield) as a colorless liquid. [α]20
D = −92.2 (c = 1.1, MeOH). H NMR (500

MHz, CDCl3) δ 3.64 (t, J = 7.7 Hz, 1H), 3.35–3.28 (m, 1H), 3.27–3.19 (m, 1H), 3.17–3.09 (m,
2H), 3.04–2.99 (m, 1H), 2.62 (dt, J = 11.0, 7.0 Hz, 1H), 1.95–1.88 (m, 1H), 1.68–1.51 (m, 2H),
1.48–1.42 (m, 1H), 1.04 (t, J = 7.2 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H). 13C NMR (125 MHz,
CDCl3) δ 12.73, 14.16, 26.50, 31.25, 40.04, 40.94, 47.63, 57.98, 173.03. HRDARTMS: Calcd
for C9H18N2O m/z 170.14191; [M+H]+ m/z 171.14979 (calcd 171.14974).
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Preparation of (S)-1-((10-bromo-7-chloro-2,3,6-trimethoxyphenanthren-9-yl)methyl)-N,Ndiethylpyrrolidine-2-carboxamide (9)

A mixture of 9-bromo-10-(bromomethyl)-2-chloro-3,6,7-trimethoxyphenanthrene (6, 0.800 g,
1.70 mmol), (S)-N,N-diethylpyrrolidine-2-carboxamide (8, 0.320 g, 1.88 mmol) and K2CO3 (1.04
g, 7.53 mmol) in DMF (24 mL) was heated to reflux for 8 h. Afterwards the mixture was allowed
to cool to room temperature, and a filtration was carried out. The resulting filtrate was then
concentrated by rotary evaporation to give a residue, from which (S)-1-((10-bromo-7-chloro2,3,6-trimethoxyphenanthren-9-yl)methyl)-N,N-diethylpyrrolidine-2-carboxamide (9, 0.650 g,
1.16 mmol, 68.2% yield) could be obtained by column chromatography (4:6 EtOAc:hexanes) as
1
a pale yellow solid. [α]20
D = −57.9 (c = 2.7, CH2Cl2 ). H NMR (500 MHz, CDCl3) δ 8.85 (s, 1H),

7.81 (s, 1H), 7.71 (s, 1H), 7.68 (s, 1H), 4.39 (dd, J = 73.7, 10.2 Hz, 2H), 4.10 (s, 3H), 4.09 (s,
3H), 4.06 (s, 3H), 3.61–3.41 (m, 3H), 3.37–3.26 (m, 2H), 3.03–2.97 (m, 1H), 2.73–2.64 (m, 1H),
2.18–2.06 (m, 1H), 1,91–1.70 (m, 3H), 1.13–1.08 (m, 6H). 13C NMR (125 MHz, CDCl3) δ 13.07,
14.53, 22.98, 29.44, 40.28, 41.21, 55.18, 55.96, 56.13, 56.18, 60.35, 64.06, 102.76, 103.03,
109.87, 123.03, 123.16, 124.69, 125.89, 126.38, 128.70, 128.90, 130.75, 149.51, 149.87, 153.45,
171.10. HRDARTMS: Calcd for C27H32BrClN2O4 m/z 562.12340; [M+H]+ m/z 563.13146 (calcd
563.13122).
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Preparation of (13aS,14S)-7-chloro-2,3,6-trimethoxy-9,11,12,13,13a,14hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (10)

TMEDA (0.660 g, 5.68 mmol) was added to a solution of (S)-1-((10-bromo-7-chloro-2,3,6trimethoxyphenanthren-9-yl)methyl)-N,N-diethylpyrrolidine-2-carboxamide (9, 1.35 g, 2.40
mmol) in dry THF (54 mL), and to this mixture a solution of 2.5 M n-BuLi in hexanes (1.94 mL,
4.85 mmol) was added carefully at -78 °C under an N2 atmosphere. The resulting mixture was
allowed to stir for 4 h. Then methanol (13.5 mL) was added, followed by NaBH4 (0.460 g, 12.2
mmol), and the reaction mixture was stirred at -40 °C for 1 h and at room temperature for 8 h.
H2O (27 mL) was then added to quench the reaction at ice bath temperature. The mixture was
extracted with CH2 Cl2 (3 × 30 mL), and the combined organic layer was dried over anhyd
MgSO4 and concentrated in vacuo. The resulting residue was further purified by column
chromatography (98:2 CH2Cl2 :CH3OH) to give (13aS,14S)-7-chloro-2,3,6-trimethoxy9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (10, 0.890 g, 2.15
mmol, 89.6% yield) as a white solid. 1H NMR (500 MHz, THF-d8) δ 7.94 (s, 1H), 7.93 (s, 1H),
7.78 (s, 1H), 7.23 (s, 1H), 4.77 (s, 1H), 4.10 (s, 3H), 4.07 (s, 3H), 3.99 (s, 3H), 3.66–3.56 (m,
1H), 3.30 (t, J = 8.2 Hz, 1H), 3.13 (d, J = 15.0 Hz, 1H), 2.45–2.41 (m, 1H), 2.33–2.23 (m, 2H),
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2.01–1.93 (m, 1H), 1.86–1.81 (m, 2H). 13C NMR (125 MHz, THF-d8) δ 21.72, 23.72, 53.10,
54.85, 55.00, 55.10, 55.29, 64.42, 65.65, 103.04, 103.96, 105.76, 121.45, 123.01, 123.49, 123.79,
126.34, 127.29, 129.41, 129.46, 149.19, 150.22, 152.91. HRDARTMS: Calcd for C 23H24ClNO4
m/z 413.13939; [M+H]+ m/z 414.14737 (calcd 414.14721).

Preparation of (E)-3-(4-acetoxy-3-methoxyphenyl)-2-(3-chloro-4-methoxyphenyl)acrylic
acid (11)

Triethylamine (16.8 mL, 119 mmol) was carefully added to a suspension of 2-(3-chloro-4methoxyphenyl)acetic acid (1, 8.40 g, 42.0 mmol) and 4-hydroxy-3-methoxybenzaldehyde (6.39
g, 42.0 mmol) in acetic anhydride (23.5 mL, 248 mmol), and the resulting mixture was stirred at
100 °C for 24 h. Afterwards the reaction was allowed to cool to room temperature, and H2O
(21.0 mL) was added dropwise. The resulting mixture was cooled to room temperature again and
extracted with CH2 Cl2 (3 × 80 mL). The organic layer was then dried over MgSO 4 and
concentrated in vacuo. The resulting residue was further purified by column chromatography
(9:1 CH2Cl2:EtOAc) to give (E)-3-(4-acetoxy-3-methoxyphenyl)-2-(3-chloro-4methoxyphenyl)acrylic acid (11, 12.6 g, 33.6 mmol, 80.0% yield) as a light-yellow solid. 1H
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NMR (500 MHz, CDCl3) δ 7.88 (s, 1H), 7.33 (d, J = 2.0 Hz, 1H), 7.11 (dd, J = 8.5, 2.0 Hz, 1H),
6.95 (d, J = 8.5 Hz, 1H), 6.91 (d, J = 8.0 Hz, 1H), 6.81 (dd, J = 8.5, 1.5 Hz, 1H), 6.66 (d, J = 1.5
Hz, 1H), 3.91 (s, 3H), 3.49 (s, 3H), 2.28 (s, 3H). 13C NMR (125 MHz, CDCl 3) δ 20.60, 55.36,
56.21, 112.27, 113.94, 122.79, 122.83, 124.54, 128.19, 129.41, 129.71, 131.64, 132.72, 140.87,
142.09, 150.64, 154.85, 168.65, 172.27. HRDARTMS: Calcd for C19H17 ClO6 m/z 376.07137;
[M+H]+ m/z 377.07892 (calcd 377.07919).

Preparation of (E)-methyl 2-(3-chloro-4-methoxyphenyl)-3-(4-hydroxy-3methoxyphenyl)acrylate (12)

To a solution of (E)-3-(4-acetoxy-3-methoxyphenyl)-2-(3-chloro-4-methoxyphenyl)acrylic acid
(11, 0.500 g, 1.33 mmol) in dry methanol (25 mL) was added 0.50 mL concd H2 SO4, the reaction
mixture was allowed to stir at 65 °C for 12 h. The mixture was then concentrated in vacuo, and
the resulting residue was purified by column chromatography (9:1 CH 2Cl2 :EtOAc) to give (E)methyl 2-(3-chloro-4-methoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)acrylate (12, 0.430 g,
1.24 mmol, 93.2% yield) as a pale-yellow solid. 1H NMR (500 MHz, CDCl3 ) δ 7.76 (s, 1H), 7.29
(d, J = 2.0 Hz, 1H), 7.10 (dd, J = 8.5, 2.0 Hz, 1H), 6.95 (d, J = 8.5 Hz, 1H), 6.76 (s, 1H), 6.46 (s,
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1H), 5.88 (s, 1H), 3.91 (s, 3H), 3.77 (s, 3H), 3.50 (s, 1H). 13C NMR (125 MHz, CDCl3 ) δ 52.34,
55.33, 56.20, 112.08, 112.28, 114.31, 122.66, 126.08, 126.62, 127.90, 129.49, 131.74, 141.16,
145.98, 147.11, 154.52, 168.25. HRDARTMS: Calcd for C18H17ClO5 m/z 348.07645; [M+H]+
m/z 349.08511 (calcd 349.08428).

Preparation of (E)-methyl 2-(3-chloro-4-methoxyphenyl)-3-(3-methoxy-4-(prop-2-yn-1yloxy)phenyl)acrylate (13)

(E)-methyl 2-(3-chloro-4-methoxyphenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylate
(12, 5.76 g, 16.5 mmol) was dissolved in 350 mL of acetone, followed by the addition of K2CO3
(21.3 g, 154 mmol). The resulting mixture was allowed to stir for 15 min at room temperature,
then a solution of 80 wt.% propargyl bromide in toluene (14.6 g, 98.2 mmol) was added
dropwise. The reaction was then stirred for 12 h at 65 °C and filtered after cooling to room
temperature. The resulting filtrate was concentrated by rotary evaporation and purified by
column chromatography (8:2 hexanes:EtOAc) to give (E)-methyl 2-(3-chloro-4methoxyphenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylate (13, 5.94 g, 15.4 mmol,
93.3% yield) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.74 (s, 1H), 7.26 (d, J = 2.0 Hz,
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1H), 7.07 (dd, J = 8.0, 2.0 Hz, 1H), 6.92 (d, J = 8.5 Hz, 1H), 6.84 (d, J = 8.0 Hz, 1H), 6.76 (dd, J
= 8.0, 1.5 Hz, 1H), 6.49 (d, J = 2.0 Hz, 1H), 4.68 (d, J = 2.0 Hz, 2H), 3.86 (s, 3H), 3.74 (s, 3H),
3.45 (s, 3H), 2.48 (t, J = 2.3 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 52.33, 55.20, 56.16, 56.39,
76.23, 78.01, 112.27, 112.93, 113.07, 122.65, 124.92, 128.17, 128.77, 129.28, 129.45, 131.65,
140.66, 147.84, 148.76, 154.55, 168.02. HRDARTMS: Calcd for C21H19 ClO5 m/z 386.09210;
[M+H]+ m/z 387.09970 (calcd 387.09993).

Preparation of methyl 7-chloro-2,6-dimethoxy-3-(prop-2-yn-1-yloxy)phenanthrene-9carboxylate (14)

To a solution of (E)-methyl 2-(3-chloro-4-methoxyphenyl)-3-(3-methoxy-4-(prop-2-yn-1yloxy)phenyl)acrylate (13, 1.42 g, 3.68 mmol) in CH2Cl2 (83 mL) was added dropwise a freshly
prepared solution of FeCl3 (4.32 g, 26.6 mmol) in EtOAc (83 mL) at -10 °C, and the reaction
mixture was allowed to stir overnight at room temperature. Afterwards H 2O (92 mL) was added,
and the mixture was stirred for 3 h at room temperature. It was then extracted with CH2Cl2 (3 ×
70 mL), and the combined organic layer was dried over anhyd MgSO 4 and concentrated in vacuo.
The resulting residue was purified by column chromatography (pure CH 2 Cl2 ) to give methyl 7chloro-2,6-dimethoxy-3-(prop-2-yn-1-yloxy)phenanthrene-9-carboxylate (14, 1.35 g, 3.51 mmol,
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95.4% yield) as a white solid. 1H NMR (500 MHz, CDCl3) δ 9.08 (s, 1H), 8.33 (s, 1H), 8.04 (s,
1H), 7.81 (s, 1H), 7.27 (s, 1H), 5.01 (d, J = 2.5 Hz, 2H), 4.11 (s, 3H), 4.03 (s, 3H), 4.01 (s, 3H),
2.63 (t, J = 2.3 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 52.20, 56.00, 56.05, 57.16, 76.64, 77.95,
103.16, 106.46, 109.72, 123.10, 123.41, 123.70, 126.12, 126.29, 128.11, 130.17, 130.41, 148.89,
150.22, 153.50, 167.61. HRDARTMS: Calcd for C21 H17ClO5 m/z 384.07645; [M+H] + m/z
385.08342 (calcd 385.08428).

Preparation of (7-chloro-2,6-dimethoxy-3-(prop-2-yn-1-yloxy)phenanthren-9-yl)methanol
(15)

A solution of methyl 7-chloro-2,6-dimethoxy-3-(prop-2-yn-1-yloxy)phenanthrene-9-carboxylate
(14, 2.42 g, 6.30 mmol) in dry THF (170 mL) was maintained under N 2 atmosphere in an ice
bath, and to this solution was added 1.0 M DIBAL-H in hexanes (25.2 mL, 25.2 mmol) dropwise.
The resulting reaction mixture was stirred overnight at room temperature. Then the reaction was
cooled in an ice bath, and Na2SO 4·10H2O was added slowly until there was no bubbles forming.
The mixture was then filtered over Celite and concentrated in vacuo to give (7-chloro-2,6dimethoxy-3-(prop-2-yn-1-yloxy)phenanthren-9-yl)methanol (15, 1.80 g, 5.06 mmol, 80.3%
yield) as a white solid. 1H NMR (500 MHz, CDCl3) δ 8.17 (s, 1H), 8.08 (s, 1H), 7.88 (s, 1H),
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7.60 (s, 1H), 7.23 (s, 1H), 5.11 (s, 2H), 4.99 (d, J = 2.5 Hz, 2H), 4.12 (s, 3H), 4.03 (s, 3H), 2.61
(t, J = 2.5 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 55.94, 56.19, 57.37, 63.99, 76.32, 78.29,
103.82, 107.28, 108.91, 122.82, 123.83, 123.96, 124.44, 125.92, 127.89, 130.23, 132.50, 147.12,
150.25, 153.49. HRDARTMS: Calcd for C20H17 ClO4 m/z 356.08154; [M]+ m/z 356.08157 (calcd
356.08154).

Preparation of 9-bromo-10-(bromomethyl)-2-chloro-3,7-dimethoxy-6-(prop-2-yn-1yloxy)phenanthrene (16)

A solution of Br2 (0.230 g, 1.44 mmol) in CH2Cl2 (2.3 mL) was added to a solution of (7-chloro2,6-dimethoxy-3-(prop-2-yn-1-yloxy)phenanthren-9-yl)methanol (15, 0.500 g, 1.40 mmol) in
CH2Cl2 (12.0 mL) at 0 °C, and the resulting mixture was stirred overnight at room temperature.
Afterwards the solvent was removed in vacuo, and the residue was purified by column
chromatography (6:4 CH2Cl2:hexanes) to give 9-bromo-10-(bromomethyl)-2-chloro-3,7dimethoxy-6-(prop-2-yn-1-yloxy)phenanthrene (16, 0.370 g, 0.750 mmol, 53.6% yield) as a
white solid. 1H NMR (500 MHz, CDCl3) δ 8.16 (s, 1H), 8.09 (s, 1H), 7.85 (s, 1H), 7.85 (s, 1H),
5.21 (s, 2H), 5.02 (d, J = 2.5 Hz, 2H), 4.13 (s, 3H), 4.09 (s, 3H), 2.62 (t, J = 2.5 Hz, 1H). 13C
95

NMR (125 MHz, CDCl3) δ 32.11, 56.09, 56.22, 57.31, 76.68, 77.92, 103.74, 106.94, 110.08,
123.57, 123.83, 124.19, 124.86, 126.30, 126.85, 129.27, 129.48, 148.04, 150.83, 153.99.
HRDARTMS: Calcd for C20 H15Br2ClO3 m/z 495.90765; [M+H]+ m/z 496.91644 (calcd
496.91547).

Preparation of (S)-1-((10-bromo-7-chloro-2,6-dimethoxy-3-(prop-2-yn-1yloxy)phenanthren-9-yl)methyl)-N,N-diethylpyrrolidine-2-carboxamide (17)

A mixture of 9-bromo-10-(bromomethyl)-2-chloro-3,7-dimethoxy-6-(prop-2-yn-1yloxy)phenanthrene (16, 0.630 g, 1.27 mmol), (S)-N,N-diethylpyrrolidine-2-carboxamide (8,
0.240 g, 1.41 mmol) and K2CO 3 (0.770 g, 5.58 mmol) in DMF (18 mL) was stirred overnight at
70 °C. Then the mixture was allowed to cool to room temperature and filtered. The resulting
filtrate was concentrated in vacuo, and the residue was further purified by column
chromatography (pure CH2Cl2 followed by 8:2 EtOAc:hexanes) to give (S)-1-((10-bromo-7chloro-2,6-dimethoxy-3-(prop-2-yn-1-yloxy)phenanthren-9-yl)methyl)-N,N-diethylpyrrolidine-2carboxamide (17, 0.670 g, 1.14 mmol, 89.8% yield) as a pale-yellow solid. [α]20
D = −46.9 (c = 2.0,
CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 8.92 (s, 1H), 8.09 (s, 1H), 7.88 (s, 1H), 7.78 (s, 1H),
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5.00 (d, J = 2.0 Hz, 2H), 4.43 (dd, J = 79.7, 12.2 Hz, 2H), 4.11 (s, 3H), 4.07 (s, 3H), 3.59–3.42
(m, 3H), 3.39–3.28 (m, 2H), 3.03–2.97 (m, 1H), 2.72–2.65 (m, 1H), 2.62 (t, J = 2.0 Hz, 1H),
2.17–2.09 (m, 1H), 1.93–1.70 (m, 3H), 1.17–1.07 (m, 6H). 13C NMR (125 MHz, CDCl3) δ 13.10,
14.57, 22.96, 29.68, 40.29, 41.22, 51.88, 55.25, 56.00, 56.13, 57.32, 64.12, 76.50, 78.13, 102.87,
107.02, 110.36, 122.83, 123.24, 124.53, 126.42, 126.95, 128.82, 129.10, 131.48, 147.17, 150.37,
153.61, 172.42. HRDARTMS: Calcd for C29H32 BrClN2O 4 m/z 586.12340; [M+H]+ m/z
587.13118 (calcd 587.13122).

Preparation of (13aS,14S)-7-chloro-2,6-dimethoxy-3-(prop-2-yn-1-yloxy)-9,11,12,13,13a,14hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (18)

To a solution of (S)-1-((10-bromo-7-chloro-2,6-dimethoxy-3-(prop-2-yn-1-yloxy)phenanthren-9yl)methyl)-N,N-diethylpyrrolidine-2-carboxamide (17, 0.600 g, 1.02 mmol) in dry THF (34 mL)
was added TMEDA (0.420 g, 3.61 mmol), and a solution of 2.5 M n-BuLi in hexanes (1.23 mL,
3.08 mmol) dropwise at -78 °C under N2 protection. The resulting mixture was stirred for 4 h at
this temperature. Afterwards methanol (8.50 mL) and NaBH 4 (0.190 g, 5.02 mmol) was added,
and the reaction mixture was allowed to stir at -40 °C for 1 h and at room temperature overnight.
97

H2O (13.0 mL) was then added carefully at 0 °C, and the mixture was extracted with CH2Cl2 (3
× 15 mL). The combined organic layer was dried with anhyd MgSO4 , and the solvent was
removed by rotary evaporation. The resulting residue was then further purified by column
chromatography (99:1 CH2Cl2 :i-PrOH) to give (13aS,14S)-7-chloro-2,6-dimethoxy-3-(prop-2yn-1-yloxy)-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (18, 0.420
g, 0.960 mmol, 94.1% yield) as a white solid. 1H NMR (500 MHz, THF-d8) δ 8.02 (s, 1H), 7.92
(s, 1H), 7.58 (s, 1H), 6.75 (s, 1H), 5.04–4.96 (m, 2H), 4.55 (d, J = 8.0 Hz, 1H), 4.08 (s, 3H), 3.99
(s, 3H), 3.18 (t, J = 7.7 Hz, 1H), 3.09 (t, J = 2.5 Hz, 1H), 2.86 (dd, J = 94.7, 14.7 Hz, 2H), 2.45–
2.37 (m, 1H), 2.10–2.00 (m, 2H), 1.99–1.89 (m, 1H), 1.78–1.67 (m, 2H). 13 C NMR (125 MHz,
THF-d8) δ 21.46, 23.52, 52.71, 54.88, 54.93, 55.31, 56.89, 64.30, 65.62, 76.01, 78.95, 102.71,
106.02, 107.55, 121.31, 122.62, 123.25, 123.50, 126.72, 128.02, 128.84, 129.34, 146.91, 150.51,
152.79. HRDARTMS: Calcd for C25H24ClNO4 m/z 437.13939; [M+H]+ m/z 438.14650 (calcd
438.14721).

Preparation of 1-(azidomethyl)-3-nitrobenzene (19)

A stock solution of 0.5 M NaN3 (0.144 g, 2.22 mmol) in DMSO (4.4 mL) was firstly prepared by
stirring at room temperature for 24 h. Afterwards 2.2 mL of this stock solution (NaN 3, 0.072 g,
1.1 mmol) was obtained, and 1-(bromomethyl)-3-nitrobenzene (0.430 g, 2.00 mmol) was added.
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The resulting mixture was allowed to stir overnight at room temperature, and H2O (5.0 mL) was
then added dropwise. The mixture was cooled to room temperature and extracted with Et2O (3 ×
3.0 mL). The resulting combined organic layer was washed with water (2 × 3.0 mL) and brine
(3.0 mL), and the organic layer was dried over MgSO4 and concentrated via rotary evaporation
to give the crude 1-(azidomethyl)-3-nitrobenzene (19, a yield of 66.7% by 1 H NMR integration).
The crude product was used in the following step without further purification. HRDARTMS:
Calcd for C7H6N4O2 m/z 178.04908; [M+H]+ m/z 179.05668 (calcd 179.05690).

Preparation of (13aS,14S)-7-chloro-14-hydroxy-2,6-dimethoxy-10-(2-nitrobenzyl)-3-((1-(3nitrobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-10,11,12,13,13a,14-hexahydro-9Hdibenzo[f,h]pyrrolo[1,2-b]isoquinolin-10-ium bromide (20a)

To a solution of (13aS,14S)-7-chloro-2,6-dimethoxy-3-(prop-2-yn-1-yloxy)-9,11,12,13,13a,14hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (18, 0.200 g, 0.460 mmol) in CH3CN
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(12.5 mL) was added crude 1-(azidomethyl)-3-nitrobenzene (19, 0.160 g, 0.600 mmol based on
1

H NMR integration), N,N-diisopropylethylamine (0.340 mL, 1.95 mmol) and 2,6-lutidine (0.230

mL, 1.99 mmol). The mixture was stirred for 5 min and CuI (0.01g, 0.05 mmol) was added. The
resulting mixture was stirred for 12 h at room temperature, and the solvent was then removed by
rotary evaporation. The residue was purified by column chromatography (9:1 CH 2Cl2:EtOH) to
give (13aS,14S)-7-chloro-14-hydroxy-2,6-dimethoxy-10-(2-nitrobenzyl)-3-((1-(3-nitrobenzyl)1H-1,2,3-triazol-4-yl)methoxy)-10,11,12,13,13a,14-hexahydro-9H-dibenzo[f,h]pyrrolo[1,2b]isoquinolin-10-ium bromide (20a, 0.160 g, 0.190 mmol, 41.3% yield) as a light-yellow solid.
1
[α]20
D = +98.0 (c = 0.6, CH3CN). H NMR (600 MHz, CD 3CN) δ 8.30–8.28 (m, 1H), 8.17–8.15

(m, 1H), 8.14–8.12 (m, 2H), 8.10 (s, 1H), 7.91 (s, 1H), 7.74–7.70 (m, 3H), 7.63–7.57 (m, 3H),
7.51 (d, J = 7.8 Hz, 1H), 5.72 (s, 2H), 5.63–5.60 (m, 1H), 5.51–5.45 (m, 2H), 5.05 (d, J = 16.2
Hz, 1H), 4.85 (d, J = 13.2 Hz, 1H), 4.34 (d, J = 14.4 Hz, 1H), 4.18 (d, J = 16.2 Hz, 1H), 4.11 (s,
3H), 4.09–4.05 (m, 1H), 3.99 (s, 3H), 3.89–3.85 (m, 1H), 3.32–3.25 (m, 1H), 2.74–2.66 (m, 1H),
2.58–2.43 (m, 3H). 13C NMR (150 MHz, CD3CN) δ 18.45, 21.35, 52.52, 54.49, 56.32, 56.61,
57.48, 60.79, 60.81, 62.36, 74.99, 104.57, 106.34, 106.66, 118.36, 121.44, 122.74, 123.10,
123.27, 123.92, 124.31, 124.72, 125.19, 125.72, 127.59, 127.76, 129.73, 130.22, 130.51, 130.60,
134.32, 137.78, 139.00, 143.72, 147.52, 148.40, 148.43, 150.40, 154.06. HRMS: Calcd for
C39H36ClN6O 8+ m/z 751.2283; [M]+ m/z 751.2040 (calcd 751.2283); Calcd for Br − m/z 78.9183;
[M]− m/z 78.9184 (calcd 78.9183).
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Preparation of (E)-methyl 3-(4-(difluoromethoxy)-3-methoxyphenyl)-2-(3,4dimethoxyphenyl)acrylate (23)

To a solution of (E)-methyl 2-(3,4-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)acrylate
(1.14 g, 3.31 mmol) in DMF (24 mL) was added K2 CO3 (0.930 g, 6.73 mmol) and H2O (1.20
mL). Sodium chlorodifluoroacetate (1.12 g, 7.35 mmol) was carefully added to the resulting
suspension, and the mixture was heated to 80 °C and stirred for 16 h. After cooling to room
temperature the reaction was diluted with H2O and extracted with CH2 Cl2 (3 × 20 mL). The
combined organic layer was washed with water and brine, dried over MgSO 4, filtered and
concentrated in vacuo. The residue was then purified by column chromatography (9:1
CH2Cl2:hexanes) to give (E)-methyl 3-(4-(difluoromethoxy)-3-methoxyphenyl)-2-(3,4dimethoxyphenyl)acrylate (23, 0.450 g, 1.14 mmol, 34.4% yield) as a white solid. 1H NMR (500
MHz, CDCl3) δ 7.74 (s, 1H), 6.98 (d, J = 8.0 Hz, 1H), 6.90 (d, J = 8.0 Hz, 1H), 6.78 (dd, J = 8.0,
2.0 Hz, 1H), 6.76 (dd, J = 8.5, 2.0 Hz, 1H), 6.74 (d, J = 1.5 Hz, 1H), 6.61 (d, J = 2.0 Hz, 1H),
6.50 (t, J = 75.0 Hz, 1H), 3.89 (s, 3H), 3.80 (s, 3H), 3.79 (s, 1H), 3.48 (s, 3H). 13C NMR (125
MHz, CDCl3) δ 52.44, 55.40, 55.91, 55.94, 111.52, 112.81, 113.96, 115.81 (t, J = 258.9 Hz),
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121.41, 122.14, 124.25, 128.03, 132.29, 133.02, 139.13, 140.33, 148.85, 149.31, 150.21, 168.19.
HRDARTMS: Calcd for C20 H20F2O 6 m/z 394.12279; [M+H]+ m/z 395.13045 (calcd 395.13062).

Preparation of methyl 3-(difluoromethoxy)-2,6,7-trimethoxyphenanthrene-9-carboxylate
(24)

A solution of (E)-methyl 3-(4-(difluoromethoxy)-3-methoxyphenyl)-2-(3,4dimethoxyphenyl)acrylate (23, 4.70 g, 11.9 mmol) in CH2Cl2 (280 mL) was cooled to -10 °C,
and to this solution was added a freshly prepared solution of FeCl 3 (15.5 g, 95.6 mmol) in EtOAc
(280 mL), and the resulting mixture was stirred overnight at room temperature. Afterwards H2O
(250 mL) was added and the mixture was stirred for 3 h at room temperature. Extraction of the
mixture with CH2Cl2 (3 × 200 mL) was carried out, and the combined organic layer was dried
over MgSO 4 and concentrated in vacuo. The residue was purified by column chromatography
(pure CH2Cl2) to give methyl 3-(difluoromethoxy)-2,6,7-trimethoxyphenanthrene-9-carboxylate
(24, 4.40 g, 11.2 mmol, 94.1% yield) as a light-yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.42
(s, 1H), 8.16 (s, 1H), 7.98 (s, 1H), 7.54 (s, 1H), 7.14 (s, 1H), 6.74 (t, J = 75.0 Hz, 1H), 4.05 (s,
3H), 4.03 (s, 3H), 3.99 (s, 3H), 3.95 (s, 3H). 13 C NMR (125 MHz, CDCl3) δ 52.08, 55.74, 55.75,
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55.88, 102.37, 106.57, 110.30, 114.94, 116.23 (t, J = 258.4 Hz), 123.52, 124.35, 125.10, 126.08,
127.83, 129.41, 141.64, 149.24, 149.31, 149.60, 167.79. HRDARTMS: Calcd for C 20H18F2O6
m/z 392.10714; [M+H]+ m/z 393.11451 (calcd 393.11497).

Preparation of (3-(difluoromethoxy)-2,6,7-trimethoxyphenanthren-9-yl)methanol (25)

To a solution of methyl 3-(difluoromethoxy)-2,6,7-trimethoxyphenanthrene-9-carboxylate (24,
4.15 g, 10.6 mmol) in dry THF (285 mL) maintained under an N2 atmosphere at 0 °C was added
a solution of 1.0 M DIBAL-H in hexanes (42.0 mL, 42.0 mmol). The resulting mixture was
allowed to stir overnight at room temperature. The mixture was then cooled to 0 °C, and
Na2SO4·10H2O was added to quench the reaction (until there were no bubbles forming). The
resulting mixture was filtered over Celite and concentrated in vacuo to give (3(difluoromethoxy)-2,6,7-trimethoxyphenanthren-9-yl)methanol (25, 3.80 g, 10.4 mmol, 98.1%
yield) as a white solid. 1H NMR (500 MHz, CDCl3) δ 8.17 (s, 1H), 7.77 (s, 1H), 7.58 (s, 1H),
7.46 (s, 1H), 7.25 (s, 1H), 6.72 (t, J = 75.3 Hz, 1H), 5.11 (s, 2H), 4.11 (s, 3H), 4.04 (s, 3H), 4.00
(s, 3H). 13 C NMR (125 MHz, CDCl3) δ 55.94, 55.98, 55.99, 64.38, 103.23, 104.61, 109.56,
115.62, 116.40 (t, J = 258.1 Hz), 123.09, 124.17, 124.28, 125.12, 129.58, 134.39, 140.00, 149.07,
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149.44, 149.75. HRDARTMS: Calcd for C19H18 F2O5 m/z 364.11223; [M]+ m/z 364.11246 (calcd
364.11223).

Preparation of 9-bromo-10-(bromomethyl)-6-(difluoromethoxy)-2,3,7trimethoxyphenanthrene (26)

A solution of Br2 (0.230 g, 1.44 mmol) in CH2Cl2 (2.5 mL) was added to a solution of (3(difluoromethoxy)-2,6,7-trimethoxyphenanthren-9-yl)methanol (25, 0.500 g, 1.37 mmol) in
CH2Cl2 (12.0 mL) at 0 °C, and the resulting mixture was stirred overnight at room temperature.
Afterwards the solvent was removed by rotary evaporation, and the residue was purified by
column chromatography (pure CH 2Cl2) to give 9-bromo-10-(bromomethyl)-6(difluoromethoxy)-2,3,7-trimethoxyphenanthrene (26, 0.420 g, 0.830 mmol, 60.6% yield) as a
light-yellow solid. 1H NMR (600 MHz, CDCl3) δ 8.23 (s, 1H), 7.92 (s, 1H), 7.78 (s, 1H), 7.49 (s,
1H), 6.76 (t, J = 75.0 Hz, 1H), 5.26 (s, 2H), 4.13 (s, 3H), 4.10 (s, 3H), 4.09 (s, 3H). 13 C NMR
(150 MHz, CDCl3 ) δ 32.64, 56.07, 56.11, 56.15, 103.20, 105.22, 110.94, 115.68, 116.09 (t, J =
259.5 Hz), 122.47, 124.38, 124.50, 125.20, 128.56, 131.12, 140.97, 149.61, 150.02, 150.45.
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HRDARTMS: Calcd for C19 H16Br2 F2O4 m/z 503.93834; [M+H]+ m/z 504.94661 (calcd
504.94617).

Preparation of (S)-1-((10-bromo-3-(difluoromethoxy)-2,6,7-trimethoxyphenanthren-9yl)methyl)-N,N-diethylpyrrolidine-2-carboxamide (27)

To a solution of 9-bromo-10-(bromomethyl)-6-(difluoromethoxy)-2,3,7-trimethoxyphenanthrene
(26, 1.40 g, 2.78 mmol) in DMF (50 mL), (S)-N,N-diethylpyrrolidine-2-carboxamide (8, 0.560 g,
3.29 mmol) and K2 CO3 (1.68 g, 12.2 mmol) were added, and the resulting mixture was allowed
to stir overnight at 70 °C. Afterwards the mixture was cooled to room temperature and filtered,
the resulting filtrate was concentrated via rotary evaporation. The residue was further purified by
column chromatography (pure CH2Cl2 followed by 6:4 EtOAc:hexanes) to give (S)-1-((10bromo-3-(difluoromethoxy)-2,6,7-trimethoxyphenanthren-9-yl)methyl)-N,N-diethylpyrrolidine2-carboxamide (27, 1.37 g, 2.31 mmol, 83.1% yield) as a white solid. [α]20
D = −41.5 (c = 3.5,
CH2Cl2). 1H NMR (600 MHz, CDCl3) δ 8.56 (s, 1H), 8.20 (s, 1H), 7.93 (s, 1H), 7.68 (s, 1H),
6.74 (t, J = 75.0 Hz, 1H), 4.45 (dd, J = 108.3, 12.3 Hz, 2H), 4.20 (s, 3H), 4.10 (s, 3H), 4.06 (s,
3H), 3.48–3.42 (m, 2H), 3.41–3.31 (m, 3H), 2.90–2.87 (m, 1H), 2.65 (q, J = 8.4 Hz, 1H), 2.15–
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2.09 (m, 1H), 1.88–1.67 (m, 3H), 1.17 (t, J = 6.9 Hz, 3H), 1.12 (t, J = 6.9 Hz, 3H). 13 C NMR
(150 MHz, CDCl3 ) δ 13.16, 14.81, 22.81, 29.75, 40.29, 41.34, 51.60, 55.91, 56.04, 56.15, 56.95,
64.12, 102.05, 108.48, 111.19, 115.46, 116.29 (t, J = 258.5 Hz), 121.73, 123.89, 124.98, 126.82,
128.57, 133.46, 140.13, 149.46, 149.70, 149.83, 172.05. HRDARTMS: Calcd for
C28H33BrF2N2O5 m/z 594.15409; [M+H]+ m/z 595.16142 (calcd 595.16192).
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PART TWO. THE STRUCTURE-BASED
APPROACH
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ABSTRACT
In the structure-based approach, a biotinylated DCB-3503 analogue was designed and
synthesized previously in Dr. David Baker’s lab, and it was utilized by our collaborators, Dr.
Yung-Chi Cheng of Yale University School of Medicine, to snare a protein targeted by DCB3503 type compounds. In order to explore a new dimension, the biotinylated DCB-3503 was
used to study the hepatitis C virus (HCV), which is closely associated with the development of
hepatic (liver) cancer and may be an etiologic factor in hepatic cancer development. A cellular
heat shock cognate protein 70 (Hsc70) was identified as one of the target proteins of DCB-3503
in the anti-HCV study. The target protein was then synthesized without and with 15N labeling in
our lab, and the thermodynamic and NMR studies of its interactions with DCB-3503 were
carried out. However, failure to elucidate the specific DCB-3503 and Hsc70 interactions by
NMR studies prompted us to turn to computational simulations, where two docking models,
including the one based on DCB-3503 and the ATP-state Hsc70 nucleotide binding domain
(NBD), and another based on DCB-3503 and the apo-state Hsc70 NBD, were constructed. The
most reasonable docking pose of DCB-3503 was generated in the ATP-state protein based on the
analysis of both the experimental observations and the docking scores. Design of more promising
active candidates can likely be realized in the future through the study of the aforementioned
docking pose.
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I. BACKGROUND
1. The Identification of the Target of DCB-3503.
Based on the facts that no specific target for DCB-3503 had been identified, a structure-based
approach was launched by collaborating with Dr. Yung-Chi Cheng of Yale University School of
Medicine. A biotinylated DCB-3503 was designed and synthesized in Dr. Baker’s group from
DCB-3509 with a biotin probe installed via CuAAC click chemistry as shown in Scheme 33. The
biotin probe was determined to be installed at the 3-position on DCB-3503 due to the previous
structure–activity studies and CoMFA predictions.14 Extensive structure–activity studies on
phenanthroindolizidine alkaloids all point to the indolizidine ring system, as opposed to the
phenanthrene system, as the pharmacophoric group.15-18 With the biotinylated DCB-3503 in hand,
our collaborators in Dr. Cheng’s lab opted to investigate a new system—the hepatitis C virus
(HCV), which is closely associated with the development of hepatic (liver) cancer and may be an
etiologic factor in hepatic cancer development.50 By studying the anti-HCV related activities of
DCB-3503, it was hoped to open a new dimension to explore, as a promising drug candidate with
both anti-viral and anticancer activities could possibly be derived. It is worth noting that due to a
lack of the corresponding anti-HCV activities of the tylophorine analogues used in construction
of the previous CoMFA models, a ligand-based approach is not feasible here.
The procedures to identify the target of DCB-3503 are described in the flowchart below. The
biotinylated DCB-3503 was firstly immobilized on the streptavidin resin through the binding
between biotin and streptavidin, which possesses an unusually high affinity (Kd = 10-15 M).51 In a
typical experiment the resulting matrix with biotinylated-tethered DCB-3503 as the probe is

109

incubated with the cell lysate of interest whereby the target protein binds to the corresponding
probe, which would be the DCB-3503 moiety. The target protein–biotinylated DCB-3503–
streptavidin complex could then be denatured and eluted by SDS-PAGE loading buffer, and the
resulting affinity-purified complex could be further resolved via SDS-PAGE analysis. The target
protein bands obtained from SDS-PAGE analysis can be further analyzed by mass spectrometry
to identify the target protein. After the identification of the protein a western blot analysis is
carried out on the elution buffer obtained from respectively passing the cell lysate and the
recombinant target protein through the DCB-3503 affinity matrix to confirm the identity of the
protein.
DCB-3503 and its analogues show an inhibitory effect against HCV. The mode of action of
the inhibition is at the elongation phase of protein synthesis and the replication of HCV on the

Scheme 33. The synthesis of biotinylated DCB-3503.3
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Figure 33. The workflow of DCB-3503 target protein identification.3
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endoplasmic reticulum (ER).52 The above-mentioned procedure using the DCB-3503 probe was
carried out by incubating the streptavidin-biotin-DCB-3503 matrix in Huh-luc/neo-ET cell lysate,
and the cellular heat shock cognate protein 70 (Hsc70) was successfully identified as one of the
target proteins of DCB-3503. The exact binding domain of Hsc70 interacted with DCB-3503 was
confirmed to be the N-terminal nucleotide binding domain (NBD) in further studies. 52

2. The Studies of Hsc70 and Its Interactions with DCB-3503.
The Hsc70 protein is a constitutively expressed chaperone protein belonging to the family of
heat shock protein 70 (Hsp70), which is classified based on the molecular weight in the units of
kDa. Hsc70 is constituted of a 44 kDa N-terminal nucleotide-binding domain (NBD) and an 18
kDa substrate-binding domain (SBD) connected via a flexible linker, and a 10 kDa C-terminal
domain functioning as a “lid” of the SBD. Although Hsc70 and Hsp70 proteins share 85% amino
acids similarity with the major distinction appearing on the C-terminal domain, the two are
believed to have different functions.53

SBD

Linker

NBD

Nucleoside triphosphate

Figure 34. The structure of E. Coli Hsp70 (DnaK) in ADP-bound state.4
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As one of the Hsp70 molecular chaperone family of proteins presented in all domains of life,
Hsc70 is involved in signal transduction in cells and apoptosis, growth and differentiation of
cells by folding, refolding and trafficking proteins through an allosteric mechanism associated
with ATP hydrolysis.54-56 Recently it was discovered that the Hsp70 family is linked to the
development of cancer and neurodegenerative diseases such as Alzheimer’s, Parkinson’s and
Huntington’s.57 It is believed that by binding ATP on the NBD of Hsc70, the SBD was able to
capture and release the substrate rapidly, whereas by hydrolyzing of ATP to ADP at the NBD,
the SBD could seize the substrate tightly. As can be seen in Figure 35, the chaperone activity
could be realized by repeating the cycle of catching the substrate at SBD by hydrolyzing ATP to
ADP, releasing of ADP and binding of new ATP molecule in order to release the substrate.

Figure 35. The functional cycle of Hsc70.
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However, due to the slow rate of releasing ADP by Hsc70 itself, nucleotide exchange factors
(NEFs) such as GrpE, Hsp110s and Bcl-2-associated athanogene (BAG) family proteins usually
play a significant role in the cycle.56, 58 In addition, J co-chaperones, including J domain protein,
could accelerate the cycle via stimulating the hydrolysis of ATP by binding to the NBD.59
Several studies have been conducted in attempts to elucidate the specific mechanisms by which
conformational change of NBD results from the hydrolysis of ATP. The process ultimately leads
to the allosteric conformational change of the SBD, quite possibly through the linker, the
majority of the steps in the process still remains unknown.4, 54, 55, 57, 60
Studies of how DCB-3503 interacting with Hsc70 NBD were carried out in Dr. Cheng’s lab
after the successful identification of the target protein. In their studies it was found DCB-3503
was bound to the NBD of Hsc70 but not to the ATPase-active pocket to stimulate the ATPase
activity. This was supported by the introduction of the mutation D206S at the ATPase pocket,
which did not affect the binding of DCB-3503. However, the binding might be affected by ATP
concentration and ionic strength. Additionally, it was found Hsc70 SBD bound to the poly U/UC
motif of HCV RNA, which is essential to the efficient translation and replication of HCV in host
cells. Given the results obtained and the fact that host chaperones and co-chaperones play
important roles in the assembly of the HCV viral replication complex, a model was proposed
about the mechanism of how DCB-3503 exhibits its anti-HCV activity. Upon treatment, DCB3503 binds to the NBD of Hsc70 to stimulate ATP hydrolysis in the presence of the poly U/UC
motif of HCV RNA, resulting in the tight binding of the corresponding HCV RNA to the SBD,
which ultimately inhibits the translation of HCV in the host cells. However, due to the narrow
selective index of approximate 3-fold (EC50 against HCV replication to IC50 against Huhluc/neo-ET cell), DCB-3503 may not be significantly beneficial as an antiviral drug to the
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patients already infected with HCV, but will have a special advantage toward the treatment of
cancer or autoimmune diseases in patients already infected with HCV. 52
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II. STATEMENT OF THE PROBLEM
Although the target protein of DCB-3503 was successfully identified, the specific binding
site and mode are still unknown due to the difficulty to obtain the co-crystal of DCB-3503 and
Hsc70 NBD for further X-ray crystallographic analysis. Therefore, the decision was made to
conduct 1H-15N HSQC NMR analysis to locate the specific binding site and possibly develop a
docking model for further drug design and screening. Several small molecules targeting the NBD
of some Hsp70 family proteins, functioning as either inhibitors or agonist, had been already
studied by NMR spectroscopy.61-63

1. The Overexpression and Purification of Hsc70 NBD.
The E. coli cell strain with the recombinant Hsc70 NBD plasmid cloned was obtained from
Dr. Cheng’s lab. The protocol of overexpression and purification of the corresponding protein
would be tested and established.

2. The Thermodynamic Studies of Hsc70 NBD.
Due to the necessity to confirm the binding between DCB-3503 and Hsc70 and the lack of
the corresponding activity assay, two types of thermodynamic experiments would be carried out.
Differential scanning calorimetry (DSC) would be conducted to confirm the ATPase activity,
and any possible binding pattern observed could also be studied. The isothermal titration
calorimetry (ITC) would also be performed to study the binding pattern in a more direct way,
and the corresponding thermodynamic statistics could be obtained from ITC as well. In both of
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the experiments the combination of different concentrations of ligand and protein would be
tested, and the interactions of the ligand with protein in different states would also be studied.

3. The Elucidation of the Interactions between DCB-3503 and Hsc70.
Once the binding was confirmed, the 1H-15N HSQC NMR experiments would be conducted
aiming at unveiling the specific interaction patterns. With the Hsc70 NBD 1H-15 N HSQC NMR
assignments provided by Dr. Erik R.P. Zuiderweg (University of Michigan, Ann Arbor), the
residues involved in the possible binding site could be located via the comparison of the NMR
chemical shifts. Since the NMR assignments offered by Dr. Zuiderweg were made on the ADPbound state protein, our NMR experiments would be carried out on ADP-bound Hsc70 as well.

4. The Construction of the Docking Model.
With the specific residues of possible binding site, a docking molecular model could be
constructed in Dr. Jerome Baudry’s lab. The evaluation of different docking poses would be
made, and further designing and screening of novel compounds based on DCB-3503 could be
carried out.
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III. DISCUSSION
1. The Overexpression and Purification of Hsc70 NBD.
The overexpression procedures of Hsc70 NBD were modified from the protocol provided by
our collaborator in Dr. Cheng’s lab. The first test of the overexpression of Hsc70 NBD was
carried out utilizing the conditions provided by our collaborator in 500 mL of lysogeny broth
(LB) media. After sufficient growth of the cells, an attempt to induce the overexpression of
Hsc70 NBD

was performed at a

final concentration of IPTG (isopropyl β-D -1-

thiogalactopyranoside) of 1.0 mM at 25 °C for 6 h (c). The cells were then harvested and lysed
via the freeze/thaw method in 50 mM Tris-HCl (pH 7.4 at 4 °C) buffer, and the resulting lysate
was centrifuged, and the supernatant and the pellet were collected. Meanwhile other possible
conditions for the overexpression of Hsc70 were tested as well. Three different conditions, which
were final concentration of IPTG 0.5 mM at 25 °C for 6 h (a), final concentration of IPTG 0.5
mM at 37 °C for 4 h (b), final concentration of IPTG 1.0 mM at 37 °C for 4 h (d), were used to
overexpress the Hsc70 NBD in 200 mL of LB media.
The three groups of cells were then harvested and lysed via the same method used in the first
test, and the corresponding supernatant and pellets were collected. An SDS-PAGE analysis of
the supernatant and pellets was carried out, and the result is shown in Figure 36. As can be seen,
an intense band around 45 kDa utilizing the standard lane as a reference could be observed in all
four supernatant lanes, and in combination with the weight of Hsc70 NBD (44 kDa) this band
was determined to be the target protein band. In addition, such a band could not be found in the
pellet lanes, suggesting a good solubility of Hsc70 NBD. It was not difficult to conclude that no
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major difference could be identified between four supernatant lanes in terms of their relative
intensities; therefore, the optimum set of conditions was selected as condition b, which
consumed the least IPTG and time. What is worth noting is that although the bands of the
supernatant in condition c was more intense than the others, the protein concentration of which
was regarded as the same as the others when the relative intensities were considered. The reason
behind these observations was that almost 500 mL of cell culture was lysed in condition c, while
only 200 mL of cell culture was in use for the other three, which resulted in a significant
difference between the concentrations of the first batches of protein and the other three.
The purification procedures utilizing on Ni-Sepharose column were then performed. After
loading and washing the crude lysate with wash buffer, the target protein Hsc70 NBD was eluted

Figure 36. The SDS-PAGE analysis of the overexpression of Hsc70 NBD under
different conditions. (From left to right: standard, condition a supernatant,
condition a pellet, condition b supernatant, condition b pellet, condition d
supernatant, condition d pellet, condition c supernatant, condition c pellet.)
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with an imidazole gradient buffer made in a 100-mL gradient maker from gradient buffer A (50
mM Tris-HCl (pH 7.4 at 4 °C), 500 mM NaCl, 100 mM imidazole) and gradient buffer B (50
mM Tris-HCl (pH 7.4 at 4 °C), 500 mM NaCl, 500 mM imidazole), and every 1-mL fractions
were collected. The concentration of the protein in every fraction was measured by absorbance at
280 nM, and the fractions with the highest absorbance were analyzed by SDS-PAGE analysis
with the results shown in Figure 37. Apparently Hsc70 NBD was primarily eluted in fractions
from 19 to 24 according to the isolated intense bands shown in Figure 37. However, in order to
obtain a clearer picture of the elution of the protein, another SDS-PAGE analysis was carried out
on fractions 12 to 24. Unfortunately not only the target protein, but also some impurities, were
eluted together by the gradient imidazole buffer according to the SDS-PAGE analysis. It was
therefore difficult to elute Hsc70 NBD exclusively using a buffer with a fixed concentration of
imidazole if the gradient buffer would not achieve a satisfactory result. The decision was then
made to elute most of the target protein bound to the Ni-Sepharose resin by utilizing an elution
buffer constituted of 50 mM Tris-HCl (pH 7.4 at 4 °C), 250 mM imidazole and 500 mM NaCl, in
which the imidazole concentration was estimated from the concentration of imidazole that was
able to start eluting the target protein in the SDS-PAGE analysis shown in Figure 38. By
collecting this eluted solution we were able to obtain the protein with the least impurities
according to the SDS-PAGE analysis.
In order to further purify the target protein from the protein mixture obtained from the NiSepharose column, gel filtration chromatography was performed by taking advantage of the size
difference between Hsc70 NBD and the rest of the impurities. The gel filtration chromatography
buffer was selected as the same buffer being used in the experiment in the next step (50 mM
Tris-HCl (pH 7.4 at 4 °C) and 100 mM NaCl or 50 mM MOPS (pH 7.4 at 4 °C) and100 mM
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Figure 37. The SDS-PAGE analysis of the purification of Hsc70 NBD via a NiSepharose column. (From left to right: standard, supernatant, pellet, supernatant flowthrough, wash buffer flow-through, fractions 19, 21, 24, 26, 28, 31, stripping buffer
flow-through.)

Figure 38. The SDS-PAGE analysis of the fractions 12 to 24 obtained from a NiSepharose column. (From left to right: standard, fractions 12 to 24.)
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NaCl based on different usages of the protein) so as to eliminate the further dialysis procedures.
The results of the separation are shown in Figure 39, and fractions from each peak were analyzed
by SDS-PAGE. It was apparent that the second peak in the gel filtration chromatogram contained
Hsc70 NBD and the third peak was determined to be the peak of imidazole as seen in Figure 40.
In addition fractions from 5 to 19 were also analyzed by SDS-PAGE to assist in making the
decision to collect and pool fractions from 9 to 14 together. Although a small amount of
impurities were still presented in the pooled fraction, the protein was determined to be pure
enough to be utilized in future experiments.

Figure 39. Separation of Hsc70 NBD obtained from gel filtration chromatography.

2. Differential Scanning Calorimetry (DSC) Studies.
Four DSC experiments were carried out aiming at studying the activities of Hsc70 NBD and
the corresponding interactions with DCB-3503. In each of the experiments the thermal unfolding
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Figure 40. The SDS-PAGE analysis of the gel filtration chromatography. (From
right to left: supernatant, supernatant flow-through, wash buffer flow-through,
elution buffer flow-through, stripping buffer flow-through, fractions of 4, 7, 8, 9,
11, 16, 17, 56, 64 and 74.)

Figure 41. The SDS-PAGE analysis of the consecutive fractions obtained
from gel filtration chromatography. (From left to right: fraction 5 to 19.)
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(“melting”) temperature Tm of the protein in different states was measured using the identical
pure buffer as a reference. Two chambers containing the protein solution and buffer were slowly
heated, and more heat was allowed to flow into the chamber with protein solution as the protein
began to unfold, which provided a thermogram of heat flow vs. temperature with the Tm as the
temperature at the peak. In Figure 42 four resulting thermograms with the Tm of apo (A), DCB3503-bound (B), ADP-bound (C) and ADP- plus DCB-3503-bound (D) states proteins are shown.
It is apparent that the Tm of the protein increased dramatically from 47 °C to 57 °C after the
binding of ADP by comparing diagrams A and C, suggesting the ATPase activity of the isolated
Hsc70 NBD. The same trend was observed in diagrams B and D as well. However, when it came
to the comparison of A and B or C and D, which indicated the binding pattern of DCB-3503 to
the protein, no obvious changes of Tm were observed. Although at the beginning section of the
diagram the curves between A and B or C and D were slightly different, the binding of DCB3503 would not affect the Tm of the protein, an indication of a weaker binding, possibly on the
surface of the protein. Compared with the already known ADP binding pattern, which was deep
into the cleft of the protein, DCB-3503 might only bind to the surface of the protein, making it
unable to influence the unfolding process of the protein. What is worth mentioning is that all four
protein solutions turned cloudy after the experiment, suggesting the denaturation of this protein
is irreversible.

3. Isothermal Titration Calorimetry (ITC) Studies.
The ITC experiment, which is a more direct way to detect the binding of DCB-3503 to Hsc70
NBD, was carried out. In ITC experiments the ligand solution is titrated into the protein solution
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Figure 42. DSC studies of the interactions between ATP, DCB-3503 and Hsc70
NBD. (A: apo; B: DCB-3503 bound; C: ADP bound; D: DCB-3503 and ADP
bound.)

125

sitting in a cell, and the heat generated by the interactions of the ligand and protein is measured
in comparison with the reference cell, and the corresponding thermodynamic statistics are
derived. Therefore, it was extremely important to keep the buffer components in the ligand
solution identical to the ones in the protein solution to avoid unnecessary noise heat.
Due to the poor solubility of DCB-3503 in aqueous media, DMSO was used to dissolve a
quantitative amount of ligand by gentle heating, and the DMSO solution was further diluted by
addition to aqueous buffer at room temperature. Additionally, the DCB-3503 DMSO stock
solution was prepared freshly before the experiments because of the instability of this ligand.
Since the final concentration of DMSO (v/v 5%) should be the same in both the ligand solution
and the protein solution, DMSO was slowly added into the protein solution to make the final
concentration as 5%.
The first attempted group of ITC experiments started with the titration of 250 µM DCB-3503
solution, the concentration of which was estimated to saturate the protein, into a 25 µM apo
Hsc70 NBD solution. All the raw ITC data were processed by the NITPIC program. From the
ITC data, however, it was obvious that saturation was not reached and no baseline could be
drawn to further calculate the thermodynamics. Therefore, a more concentrated DCB-3503
DMSO stock solution was prepared, and the corresponding concentration of the 5% DMSO
aqueous DCB-3503 solution was increased to 500 µM. The titration was done on the 25 µM apo
protein solution as well. To our surprise the saturation of the titration was still not reached, even
with the ligand concentration doubled. Thus new ITC experiments were designed.
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Figure 43. The results obtained from the first group of ITC studies. (Top: titration
of 250 µM DCB-3503 into 25 µM apo Hsc70 NBD; Bottom: titration of 500 µM
DCB-3503 into 25 µM apo Hsc70 NBD.)
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In order to saturate the protein solution, a protein solution with lower concentration than the
one used previously was prepared. An experiment of titrating 500 µM DCB-3503 solution into
15 µM apo protein solution was performed. As can be seen in Figure 44 no saturation was
reached in the experiment. Thus two more experiments of titrating 500 µM DCB-3503 solution
into 7.5 µM apo protein solution and 5 µM apo protein solution respectively were carried out.
Surprisingly in neither of the experiments was saturation reached. The suspicion then fell onto
the possible heat generated by dilution of DCB-3503 into a larger quantity of water. Then one
more experiment was performed to prove the above-mentioned theory, as 500 µM DCB-3503
solution was titrated into pure 5% DMSO buffer without the presence of any protein. As
predicted, significant heat signals were observed in the experiment as can be seen in Figure 44.
Thus it was concluded due to the highly hydrophobic structure of DCB-3503, although it was
diluted into aqueous buffer before titration, it could still bring significant enthalpy change into
the system when it was further diluted, which generated huge level noise in the results.
By knowing the cause of the problem, an additional group of experiments were carried out,
in which one was the titration of 500 µM DCB-3503 into 5% DMSO buffer and one was the
titration of 500 µM ligand into 31 µM apo protein solution with 5% DMSO. It was important to
point out that a single batch of DCB-3503 aqueous solution was prepared from one DMSO stock
solution freshly prepared, and in both of the experiments the DCB-3503 solution used to titrate
the protein was obtained from the above-mentioned single batch in order to eliminate possible
differences in the concentration of the ligand between solutions prepared in two batches, which
could generate huge errors in the ITC studies. The raw ITC data were processed by the NITPIC
and SEDPHAT programs, and a global fit was carried out on both experiments. The injection
heat data was obtained by subtracting the reference data from the data obtained with protein
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Figure 44. The results obtained from the second group of ITC studies. (Top left:
titration of 500 µM DCB-3503 into 15 µM apo Hsc70 NBD; Bottom left: titration of 500
µM DCB-3503 into 7.5 µM apo Hsc70 NBD; Top right: titration of 500 µM DCB-3503
into 5 µM apo Hsc70 NBD; Bottom right: titration of 500 µM DCB-3503 into buffer.)
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solution, and the resulting data were plotted as shown in Figure 45. It was apparent that no
baseline was able to be reached in this group of experiments; therefore, the corresponding
thermodynamics were not obtained. A second group of experiments conducted on ADP-bound
protein was also performed, as ADP was added into both reference and actual experiments to a
same final concentration of 290 µM. As can be seen in Figure 45, the data from the reference
experiment show no considerable differences from those of the reference sample in the apo
protein experiment. However, the binding pattern changed significantly when ADP was present,
as an endothermic signal increased with the injection to compete with the heat generated by
dilution of DCB-3503. It was concluded that a complex binding pattern was obtained when
DCB-3503 interacts with the ADP-bound protein, which precludes the calculation of the
thermodynamic parameters.
Although problems were present in titration of Hsc70 NBD by DCB-3503, the binding
pattern of DCB-3503 to both apo and ADP-bound protein revealed the existence of the binding,
and a complicated mechanism is indicated between the macromolecule and the small ligand,
especially in the presence of ADP where an endothermic signal played a large role at the end of
the titration. The major problems could be illustrated as the following. First of all, because of the
poor solubility of DCB-3503, it was not possible to further increase the ligand concentration.
Additionally, in order to keep the protein active the concentration of the protein needed to be
kept above 22 µM (1 mg/mL). Those facts made the saturation of the titration difficult to achieve,
especially in a weak-binding pattern scenario. Secondly, the preliminary ITC results showed an
entropy-driven binding instead of an enthalpy-driven one. The lack of abundant H-bond donors
and the large aromatic system made the interactions more likely to be hydrophobic in nature
rather hydrophilic involving H-bond breaking and formation, which make the process an
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Figure 45. The results obtained from the third group of ITC studies. (Top left: titration
of 500 µM DCB-3503 into buffer; Bottom left: titration of 500 µM DCB-3503 into 31
µM apo Hsc70 NBD; Top right: titration of 500 µM DCB-3503 into buffer with ADP;
Bottom right: titration of 500 µM DCB-3503 into 31 µM ADP bound Hsc70 NBD.)
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Figure 46. The ITC data plot obtained from the subtraction of apo Hsc70 data (bottom left in Figure 43) from
the reference data (top left in Figure 43).
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entropy-driven one. Since the heat released and observed in ITC was largely a change in
enthalpy, with a high heat of dilution from the ligand as a huge background noise, it was difficult
to accurately measure the enthalpy change of the ligand–protein interactions.

4. NMR (1H-15N HSQC) Studies.
Three 1H-15N HSQC experiments were carried out on the ADP-bound Hsc70 NBD in order
to best correlate the assignments provided by Dr. Zuiderweg that were obtained on the ADPbound protein. The results are shown in Figure 47, as the spectrum of the ADP-bound protein (A)
was firstly collected, then the spectra of the ADP-bound protein with an estimation of 50% (B)
and 100% (C) DCB-3503 saturation were collected after the injection of the corresponding
DCB-3503 DMSO solution. To better analyze the results, alignments of spectra A and B, A and
C, B and C and A, B and C were performed. However, no significant changes of the chemical
shifts of the peaks were observed. In addition, compared with the 1H-15N NMR assignments of
the chemical shifts of Hsc70 provided by Dr. Zuiderweg, a considerable number of peaks were
missing in the current spectra. It was considered that these spectra were the ones of soluble
dimers of Hsc70 due to the peaks crowding in the center area, and these soluble dimers were
believed to be formed during the inevitable concentration step where high pressure was applied
to the protein solution obtained from gel filtration chromatography. Although the concentration
of the protein measured on spectrophotometer at the absorbance of 280 nM was high enough to
obtain a good NMR spectrum, most likely it was the soluble dimer that contributed to the high
concentration, leaving not enough monomer in the solution to give an adequate spectrum.
However, because of the similar protein preparation procedures and the observed activities in the
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Figure 47. 1H-15N HSQC spectra and the corresponding alignments. (I. A; II. B; III. C;
IV. A and B; V. A and C; VI. B and C; VII. A, B and C.)
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DSC and ITC experiments, the surface of the monomer where the dimers joined were believed to
be a considerable distance away from the ATP or DCB-3503 binding sites.

5. Construction of the Docking Models.
5.1. The Introduction of Docking.
Docking is an important tool designed for structure-based drug design with the purpose of
simulating the interactions between a small-to-medium-size molecule (ligand) and a not-tooflexible macromolecular target (receptor), which is usually a protein. It is able to generate
different orientations and conformations of the ligand within the binding site of the target
molecule to calculate the optimal binding geometries and energies for further optimization of the
ligand molecules. In the docking model, several poses of the ligand can be generated, and the
score of each will be calculated as a free energy of binding. The docking model in our study was
built in a MOE 2012.10 environment. A reliable docking model can be built when the ligand has
limited flexibility (up to 10 rotatable bonds) and the active binding site is allowed to move (side
chains can be flexible, while the backbone is always fixed). 64
Unfortunately, in our study not enough experimental information was obtained to elucidate
the specific binding site of DCB-3503 to Hsc70 NBD; therefore Site Finder was utilized to
identify the potential binding site. Site Finder is a program devised to calculate the possible
active binding site in a receptor from the 3D atomic coordinates of the receptor. It is a geometric
method to identify the potential binding site with a work flow shown as follows: 1. Identify the
tight atomic packing regions as potential sites and exclude the ones “too exposed” to solvent; 2.
Classify the sites as hydrophobic and hydrophilic; 3. Calculate and eliminate the inappropriate
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alpha spheres, which are the associated spheres generated by the collection of four points
produced by the triangulation of the 3D points in the selected sites; 4. Classify the alpha spheres
as hydrophobic and hydrophilic followed by the corresponding clustering to produce the sites; 5.
Rank these sites by the amino acid composition of the pocket.64

5.2. The Docking Model Constructed with ATP.
Before the construction of the model, the ligand and protein need to be properly prepared.
The ligand DCB-3503 was built by Molecule Builder in MOE 2012.10, and the corresponding
energy was minimized by the MMFF94x force field. The X-ray crystal structure of Hsc70 NBD
was obtained from the Protein Data Bank (PDB) with the code of 1NGE. The protein was then
prepared in MOE via protein structure preparation tools (Structure Preparation, Protonate 3D and
LigX). The purpose of preparing the 3D protein structure is to fix the missing or poorly resolved
atomic data. Prior to the preparation of the protein structure, all the water molecules and other
solvent molecules were deleted.
In the previous study conducted in Dr. Cheng’s lab the conclusion was made that DCB-3503
was able to stimulate the hydrolysis of ATP in Hsc70 NBD; therefore, a docking model that
includes the ATP molecule at the ATPase site was firstly constructed. The ATP was retained and
prepared together with the protein molecule, and the Site Finder was utilized to detect the
potential binding site of Hsc70 NBD in the presence of the ATP molecule. In Figure 48 the most
potential binding site [with the largest size and highest propensity for ligand binding (PLB) score
as 3.56] is shown as highlighted in the alpha sphere centers and pocket surface, respectively. The
alpha sphere centers depiction is viewed from the front of the protein, while the pocket surface
one is viewed from the side of the protein rotated 45° counterclockwise from the front view. In
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these two figures, the red spheres or surface indicated hydrophilic atoms, and the white ones
suggested hydrophobic atoms. Additionally, the ATP molecule is highlighted in light purple in
the figures. It is obvious that the most potential site was at the “entrance” of the protein cleft,
whereas the ATPase active site is at the end of the cavity. Meanwhile, the existence of a large
hydrophobic area indicates the possibility of binding of DCB-3503, which has a significant
amount of hydrophobic surface. It is worth noting that except for this site of highest potential and
a site ranking the second with a PLB score at 2.19, all the rest of the sites calculated by the
program had negative PLB scores, suggesting that these are not potential binding sites. Although
the second best site had a positive PLB score, due to its significantly smaller size of 83 (in
receptor atoms) compared with a size of 209 of the first site, the considerable quantity of
hydrophilic surface and the proximity to the ATPase active site residing the D206S mutation,
where DCB-3503 is not supposed to bind to according to the corresponding studies in Dr.
Cheng’s lab, it was not considered as a potential binding site.
With the potential binding site calculated, the docking with DCB-3503 was carried out. There
were 26 poses selected by the program as potential binding poses, with the final docking scores
ranking from -7.7315 to -5.0414 kcal/mol. The more negative the score, the more favorable the
pose is considered to be. Even though the score plays an important role in the evaluation of the
poses, whether or not the pose is able to explain the experimental observation is also a vital
aspect to take into consideration. After carefully examining all the poses based on the criteria
mentioned above, the pose with the second lowest score was considered to be the most
reasonable one based on a number of considerations. The most important point in selecting a
reasonable pose is to ensure the exposure of the 3-methoxy group of DCB-3503 on the protein
surface, as a biotinylated-tethered DCB-3503 molecule with a biotin linker modified from
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Figure 48. The binding site of greatest potential of apo Hsc70 NBD identified by Site
Finder. (Top alpha sphere center view; Bottom: pocket surface view.)
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a 3-methoxy group buried deep into the protein would not be able to “fish” the Hsc70 out from
the cell lysate. Although the best pose given by the program had a score of -7.7315 compared
with the second one as -7.3548, the second pose was to be considered the one of greatest
potential. Most of the poses ranking after the second one had their 3-methoxy groups buried into
the protein. The overall views of the docking pose without and with the detailed binding pocket
are shown in Figures 49 and 50, where the ATP molecule is in light purple. In Figure 49 the
overall binding is shown as the front view and the top view, respectively. It is clear that the
binding appears at the “entrance” of the ATPase active site cleft, where ATP is on the back top
side of DCB-3503. The overall view of the binding results with the amino acid residues
constituting of the binding pocket visible is shown here as well, as DCB-3503 is colored light
blue, and the nonpolar hydrogens on the protein are hidden.
Two enlarged views of the binding are displayed as well. In the first view in Figure 51, the
detailed interactions (H-bonding, hydrophobic) between DCB-3503 and the residues in the
pocket could be observed. A weak arene-H interaction between Arg264 and the B aromatic ring,
and two H-bonds including the one between the 14-hydroxyl group and Glu231 with a distance
of 3.08 Å, and the one between the nitrogen and Arg264 with a distance of 3.35 Å were
generated. Although the 3-methoxy group was close to the surface generated by His87 in the
second figure showing the surface interactions, the C–O bond could be rotated to avoid the
collision, while the linker attached to the 3-position could still be exposed. All the above
information, including the exposure of the 3-methoxy group, could be obtained from the 2D
ligand interactions analysis as well except for the arene-H interaction, which is too weak to show.
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Figure 49. The overall views of the docking pose of greatest potential of DCB3503 with ATP in light purple. (Top: front view; Bottom: top view.)
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Figure 50. The overall view of the docking pose of greatest potential of DCB-3503 (in light
blue) with ATP (in light purple) in the detailed binding pocket.
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Figure 51. The detailed view of the interactions between DCB-3503 and the
binding pocket of Hsc70 NBD. (Top: regular view of the detailed interactions;
Bottom: surface view of the detailed interactions.)
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Figure 52. The 2D view of the interactions between DCB-3503 and the
binding pocket of Hsc70 NBD with the legend shown below.
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The docking pose could also explain some of our experimental observations. The most
important question remaining is how DCB-3503 stimulates the ATP hydrolysis via binding to
Hsc70 at a site other than ATPase active site. Further studies of the docking model were carried
out through the overlapping of the DCB-3503-ATP-binding pocket complex with the originally
prepared ATP-protein before docking. By aligning the docking results with the original protein,
it was expected to observe the position changes brought by DCB-3503 onto Hsc70 and ATP. In
the overall view the backbone carbons of the original protein are shown in grey with the
corresponding ATP as light purple, and the carbons in the pocket resulting from docking are
colored as green with the related ATP as light blue. It is apparent that considerable shifts are
observed on both the amino acid residues and the ATP molecule, and by carefully examining the
details, it is found that several new H-bonding and hydrophobic interactions are created and
several old ones are eliminated. A clearer comparison is displayed in Figure 54 by 2D ligand
interactions analysis, and it is obvious that more interactions are generated between the
triphosphates and the residues constituted of the ATPase active site. Thus a model is proposed as
the following: due to the binding of DCB-3503 at the “entrance” of the cleft, the positions of the
corresponding residues are shifted, which results in allosteric position changes of the ATPase
active site residues and the ATP molecule, and as a result more interactions are built around the
triposphates moiety, which ultimately serve to accelerate the ATP hydrolysis. A similar allosteric
mechanism has been proposed before, as the binding of the ligand at the entrance of the ATPase
cleft of DnaK NBD far from the active site led to the disruption of the interaction between DnaJ
and DnaK.63
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Figure 53. The overall and detailed views of the alignment of the ATP-binding pocket
after docking with the one before docking. (The pocket with the green backbone
carbons and light blue ATP resulted from docking; the one with the grey backbone
carbons and light purple ATP belongs to the original one.)

149

Figure 54. The 2D views of the interactions between ATP and the
binding pocket. (Top: before docking; Bottom: after docking.)
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Several experimental observations could also be explained by the proposed model. In the ITC
experiment, after the binding of DCB-3503 to the protein in the presence of ADP, a secondary
event was observed primarily due to the construction of the new interactions between the ADP
molecule and the protein. Under the assumption that the same binding site and pattern were
obtained without the presence of ATP or ADP, it was not a surprise that the heat generated in the
apo state ITC experiment is not significantly large as only weak binding is present due to the
small number of H-bonds being constructed. Additionally its weak binding nature and its
exposure on the surface of the protein explains the inability of DCB-3503 to alter the melting
point of the protein in the DSC study.
In addition, the blockage at the entrance of the cleft that is considerably distant from the
ATPase active site from the results of the D206S mutation study mentioned in the introduction. It
is therefore not impossible to elute the protein bound to the biotin matrix by a high concentration
of ATP as observed in Dr. Cheng’s lab, as large number of ATP molecules would overcrowd the
cleft or alter the conformation of the protein that serves to break up the DCB-3503–protein
complex. Meanwhile the two H-bonds once again emphasized the importance of the
stereochemistry of the HO- at 14-position and the nitrogen in the tertiary amino group.

5.3. The Docking Model Constructed without ATP.
Based on the previous conclusion that DCB-3503 derived its activity by stimulating ATP
hydrolysis, it was reasonable to construct the docking model with the protein with ATP already
bound. However, a docking model without ATP at the active site was also built to better compare
the two states.
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Similar procedures and the same protein structure from the first model were utilized for
building the new model; however, before the preparation of the protein, the ATP molecule was
deleted together with water molecules. Site Finder was applied to locate the potential binding site,
and the site of greatest potential was identified as shown in Figure 55 with a PLB score of 4.29
and a size of 399. By making careful observations it was found this large binding site was
actually the combination of the ATPase active site and the potential DCB-3503 binding site
identified in the previous model. Since the occupation of the ATP in the previous model, the site
below the ATPase active site was identified instead of the whole larger binding site.
A docking model was attempted at the large binding site, and the general view of the pose of
DCB-3503 (in light blue) with the best score (-8.3457 kcal/mol) is shown in Figure 56. It is not
surprising to find the overlapping of the adenine moiety of ATP (in light purple) and DCB-3503
when the protein obtained after docking was aligned with the original protein with the ATP
molecule included. The docking details are shown in Figure 56 on the right and in Figure 57 in a
regular view and two surface views, respectively. It was obvious that DCB-3503 preferably
bound to the most hydrophobic site on the protein, i.e., the cavity where the adenine of ATP
resided, over the site identified in the previous model, as both of DCB-3503 and adenine possess
abundant aromatic systems. It is unlikely for DCB-3503 to bind to the adenine binding site if
ATP was already in place; likewise, it was impossible for ATP to bind to the ATPase active site
when DCB-3503 already occupied the hydrophobic pocket within such a narrow space. Although
this hydrophobic binding site is far away from the D206S mutant in the ATP hydrolysis site, in
consideration of the non-competitive mechanism of DCB-3503, this site was not regarded as the
possible binding site of DCB-3503. However, the possibility should not be excluded that DCB3503 would function as an inhibitor to apo Hsc70 NBD according to the above analysis, and the
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Figure 55. The binding site of greatest potential of Hsc70 NBD in the presence of ATP
identified by Site Finder. (Left: alpha sphere center view; Right: pocket surface view.
The site within the white circles is the potential site identified in the previous model.)
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Figure 56. The general (top) and detailed (bottom) views of the binding
pose of greatest potential for DCB-3503 with ADP-bound Hsc70 NBD.
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Figure 57. The detailed surface views of the binding pose of greatest
potential for DCB-3503 with ADP-bound Hsc70 NBD. (Top: top view;
Bottom: bottom view.)

155

rational design of such an inhibitor competing at the adenine binding site has been already
described.65 It is not impossible for DCB-3503 to bind to multiple sites on the apo protein,
whereas on the ATP-bound protein the most reasonable binding site is at the “entrance” of the
cleft. Further studies need to be conducted on the possible inhibition activity of DCB-3503
against apo Hsc70 NBD. The construction of this docking model of the apo protein and
examination of the possible model of DCB-3503–apo protein binding in light of the results of
experimental observations further confirm the rational nature of the first model built on the ATPbound protein.
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V. EXPERIMENTAL
1. The Overexpression and Purification of Hsc70 NBD.
The E. coli BL21 (DE3) pLysS cell strain with the six-His-tagged NBD of the recombinant
Hsc70 protein plasmid cloned in was first inoculated on a sterilized lysogeny broth (LB) agar
plate containing 50 µg/mL kanamycin and 20 µg/mL chloramphenicol as antibiotics, and the
cells were allowed to grow overnight at 37 °C. Afterwards an isolated colony grown on an LB
agar plate was transferred into 1 mL of LB with 50 µg/mL kanamycin and 20 µg/mL
chloramphenicol, and the subculture was incubated for 6–8 h at 37 °C until cloudiness in the vial
was observed. Then the 1 mL of subculture was transferred into 200 mL of LB containing 50
µg/mL kanamycin and 20 µg/mL chloramphenicol, and the resulting subculture was allowed to
grow overnight at 37 °C. The overnight subculture was then transferred into 4000 mL of LB
containing 25 µg/mL kanamycin and 20 µg/mL chloramphenicol and grown at 37 °C until the
optical density was ~0.6 at 600 nm. Then the expression of the protein was induced by the
addition of isopropyl β-D -1-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM,
and the cells were centrifuged after 4 h of induction at 37 °C. The cells were resuspended in
1600 mL 0.85% (w/v) NaCl solution and centrifuged again to give the cells ready to be stored at
-80 °C.
For the overexpression of the 15N labeled Hsc70 NBD, a 200-mL subculture was grown in
LB media followed the same procedure for preparation of the regular protein, and the cells were
then centrifuged and resuspended in 4000 mL of M9 minimal media (with 1 g/L 15NH4Cl) with
25 µg/mL kanamycin and 20 µg/mL chloramphenicol in and allowed to grow at 37 °C until the
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optical density was ∼0.6 at 600 nm. Afterwards induction of the expression of the protein was
carried out utilizing IPTG at a final concentration of 0.5 mM for 4 h, the cells were then
harvested by the procedures stated above.
The purification of Hsc70 NBD began with dissolving 0.5 L cell culture into 15 mL lysis
buffer (100 mM NaCl, 20 mM imidazole, 1mM phenylmethanesulfonylfluoride (PMSF), 1 mM
MgCl2, 20 µg/mL DNase I, 50 mM Tris-HCl (pH 7.4 at 4 °C)), and the resulting suspension was
homogenized. Afterwards the suspended cells were lysed with 3 cycles of freeze and thaw in
liquid N2 . The lysate was then centrifuged at 17,000 RPM for 1 h and the cleared supernatant
was transfer to a clean Falcon tube. The supernatant was loaded onto 1 mL of a Ni-Sepharose
(GE Healthcare Life Science, Pittsburgh, PA) column and was then washed with 150 mL of
wash buffer (100 mM NaCl, 20 mM imidazole, 50 mM Tris-HCl (pH 7.4 at 4 °C)). The Hsc70
NBD protein bound to the Ni-Sepharose was then eluted with buffer containing 500 mM NaCl,
250 mM imidazole and 50 mM Tris-HCl (pH 7.4 at 4 °C). The SDS-PAGE analysis showed
multiple impurities were eluted together with the target protein, and gel filtration
chromatography was used to further purify the protein. The gel filtration buffer with 100 mM
KCl, 5 mM MgCl2, 5 mM K3PO4 and 50 mM MOPS (pH 7.4 at 4 °C) was utilized, and the
resulting protein was further concentrated under nitrogen pressure to give pure Hsc70 NBD. The
final yield of the protein was consistently between 2.2 to 2.7 mg/L of induced cell culture.

2. Differential Scanning Calorimetry (DSC).
The DSC experiments were carried out on a VP-DSC microcalorimeter (MicroCal, Inc.) at an
external pressure of 25 psi. The starting temperature and the final temperature were set to 15 °C
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and 75 °C, respectively, and the heating rate was 1 °C/min. All the solutions were degassed at
20 °C for 15 min, and any possible precipitate was spinned down before the experiment.
A solution of Hsc70 NBD at a concentration of 23 µM in MOPS buffer (100 mM KCl, 5 mM
MgCl2, 5 mM K3PO4 , 50 mM MOPS (pH 7.4 at 4 °C)) was used. The first experiment was
performed by using the above-mentioned apo-state protein solution directly. Then the ADP-state
protein solution was prepared by adding 12 µL of 20 mM ADP aqueous stock solution to 1.2 mL
of apo protein solution to make the ADP final concentration as 200 µM, and this solution was
used in the ADP-state protein experiments. The third experiment testing the interactions between
Hsc70 NBD and DCB-3503 was carried out utilizing a solution prepared by adding 10 µL of 10
mM DCB-3503 DMSO stock solution into 1.2 mL of apo-state protein solution. The final
concentration of DCB-3503 was 83 µM in the solution. The solution used in the last experiment
was then prepared by adding 12 µL of 20 mM ADP aqueous stock solution and 10 µL of 10 mM
DCB-3503 DMSO stock solution in 1.2 mL apo protein solution, making the final concentration
of ADP and DCB-3503 as 200 µM and 83 µM, respectively.

3. Isothermal Titration Calorimetry (ITC).
The ITC experiments were performed on a VP-ITC microcalorimeter (MicroCal, Inc.) at
25 °C, and the total number of injections was set to 29. The solutions to be placed in the cell and
the syringe were degassed for 15 min at 20 °C and any possible precipitate was centrifuged
before the experiment. All the experiments were performed based on the procedures used in the
last two groups of experiments described in detail below. The corresponding components and
concentration of buffers were adjusted accordingly in each individual experiment.
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In each of the last two groups of experiments, a reference experiment and an experiment with
the protein were performed. The same protein solution (100 mM KCl, 5 mM MgCl2 , 5 mM
K3 PO4, 50 mM MOPS (pH 7.4 at 4 °C)) at a concentration of 33 µM was used in every
experiment, and the same ADP aqueous stock solution with a concentration of 40 mM was used
as well. In order to avoid the possible decomposition of DCB-3503 in DMSO over a long
duration of time, and to maintain a consistent and accurate concentration of the DCB-3503 stock
solution, two batches of DCB-3503 powder for two groups of experiments were accurately
weighed. The ligand powder was dissolved right before the experiment, and the resulting DCB3503 DMSO stock solution was then used to prepare the ligand solution used in two experiments
in one group. In the two experiments of the first group, the same ligand solution (500 µM DCB3503, 5% DMSO, 100 mM KCl, 5 mM MgCl2 , 5 mM K3 PO4, 50 mM MOPS (pH 7.4 at 4 °C))
was placed in the syringe of the VP-ITC instrument. However, a solution of protein (31 µM
Hsc70 NBD, 5% DMSO, 100 mM KCl, 5 mM MgCl 2 , 5 mM K3 PO4, 50 mM MOPS (pH 7.4 at
4 °C)) and pure buffer (5% DMSO, 100 mM KCl, 5 mM MgCl 2, 5 mM K3PO4, 50 mM MOPS
(pH 7.4 at 4 °C)) were used, respectively, in the protein experiment and in the reference
experiment. Similar procedures and solutions were used in the second group of experiments
except for the usage of 40 mM ADP stock solution. In both of the protein solution (31 µM Hsc70
NBD, 5% DMSO, 100 mM KCl, 5 mM MgCl2, 5 mM K3PO4 , 50 mM MOPS (pH 7.4 at 4 °C))
and the reference buffer (5% DMSO, 100 mM KCl, 5 mM MgCl 2, 5 mM K3 PO4, 50 mM MOPS
(pH 7.4 at 4 °C)), the corresponding ADP stock solution was added to make the final
concentration as 300 µM. In the preparation of the ligand solution (500 µM DCB-3503, 5%
DMSO, 100 mM KCl, 5 mM MgCl2 , 5 mM K3PO4, 50 mM MOPS (pH 7.4 at 4 °C)), extra
ddH 2O was required in order to keep the concentration consistent with the new concentration of
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buffer components in the protein solution generated by the addition of ADP stock solution as
mentioned above.

4. NMR (1H-15N HSQC) Studies.
The 15N labeled Hsc70 NBD was prepared, followed by the previously elaborated
overexpression and purification procedures. However, in the gel filtration chromatography the
buffer was constituted of 100 mM NaCl and 50 mM Tris-HCl (pH 7.4 at 4°C), and the same
buffer was used for the NMR studies. The NMR sample was prepared by concentrating the
diluted protein solution obtained from gel filtration chromatography to a more concentrated
solution at 186 µM, and 400 µL of this sample was obtained and centrifuged for 5 min at 13,200
rpm. Afterwards 30 µL of 150 mM ADP D2O solution and 5% DMSO (21.5 µL) were added to
finish the preparation of the sample. All the NMR experiments were carried out at 25 °C on a
600 MHz Varian VNMR spectrometer equipped with a triple-resonance cold probe. The first 1H15

N HSQC spectrum was collected for 16 h with the number of scans at 272. Before the

collection of the second 1H-15N HSQC spectrum, 4 µL of 10 mM DCB-3503 DMSO stock
solution was added slowly into the sample in the Shigemi NMR tube, and the collection was set
to 16 h with the number of scans at 272. The last spectrum was collected after the careful
addition of an extra 5 µL of 10 mM DCB-3503 DMSO stock solution into the sample, and it was
allowed to collect 23 h with the number of scans at 392. All the spectra were processed with the
SPARKY program.
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5. The Construction of Docking Models.
All the docking models were built in the MOE 2012.10 program (Chemical Computing
Group, Montreal, Canada). The ligand DCB-3503 was constructed in Molecule Builder
incorporated in MOE, and the corresponding energy was minimized in the MMFF94x force field.
The X-ray crystal structure of the protein was obtained from the Protein Data Bank (PDB) with a
code of 1NGE.
In the construction of the model with ATP-bound protein, water molecules were first deleted.
The protein was then prepared in the Structure Preparation tool followed by Protonate 3D and
LigX, and partial charges were assigned in the MMFF94x force field during the preparation.
Afterwards Site Finder was utilized to identify the most potential binding site, and instead of
selecting only receptor atoms, all atoms including those of the ATP were involved in the
calculation. Then the best potential binding site was selected, and dummy atoms were created at
the alpha sphere centers. When doing docking, these dummy atoms were chosen as the receptor
site, and the rigid receptor protocol was selected with the placement as a triangle matcher. The
London dG was selected as rescoring 1, while GBVI/WSA dG was used as rescoring 2. The
default setting of refinement was utilized except for the tether, which was set to 0.1 as to increase
the flexibility of the side chains.
In the construction of the model without ATP, the same ligand and protein and similar
procedures and settings were adopted. However, the protein was prepared after the deletion of
both water molecules and the ATP molecule, and all remaining atoms were selected when Site
Finder was used to locate the binding site of greatest potential.
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CONCLUSION
In the ligand-based approach, a CoMFA model was built based on a group of tylophorine
analogues that were believed to function on the NF-κB pathway. Several DCB-3503 analogues
with higher projective activities were designed via the CoMFA model, and the corresponding
syntheses were performed using a modification of a novel route. These novel DCB-3503
analogues were further studied by our collaborator, Dr. Yung-Chi Cheng of Yale University
School of Medicine, on their antitumor and anti-HCV activities. The analysis of the
inconsistencies of the predictive and the experimental data was made in the condition of a lack of
experimental data against NF-κB pathway, and a more complicated than anticipated mechanism
of the antitumor activities of DCB-3503 and its analogues were brought to light.
In the structure-based approach, a target protein of DCB-3503 type compounds, Hsc70, was
successfully snared by the biotinylated DCB-3503, and its active domain was subsequently
identified. Due to the inability to obtain the co-crystal structure of DCB-3503 and Hsc70 NBD
by our collaborator, the above protein was overexpressed and purified by us for further 1H -15N
HSQC NMR studies, which could possibly aid in elucidating the specific interactions between
DCB-3503 and the protein. The thermodynamic studies were also carried out on DCB-3503 and
Hsc70 NBD prior to the NMR studies. However, the failure to obtain satisfactory NMR spectra
prompted us to turn to the computational simulations. Two docking models were constructed on
the ATP-state Hsc70 NBD and the apo-state Hsc70 NBD, respectively. The most reasonable
docking pose was generated in the ATP-state protein, and more promising active candidates can
likely be designed from the model in the future.
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APPENDIX
1

H, 13C, selected 2D NMR and mass spectra
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1

H NMR spectrum (500 MHz, CDCl3) of 2-(3-chloro-4-methoxyphenyl)acetic acid (1).
174

13

C NMR spectrum (500 MHz, CDCl3) of 2-(3-chloro-4-methoxyphenyl)acetic acid (1).
175

1

H NMR spectrum (500 MHz, CDCl3) of (E)-2-(3-chloro-4-methoxyphenyl)-3-(3,4-dimethoxyphenyl)acrylic acid (2).
176

13

C NMR spectrum (125 MHz, CDCl3) of (E)-2-(3-chloro-4-methoxyphenyl)-3-(3,4-dimethoxyphenyl)acrylic acid (2).
177

1

H NMR spectrum (500 MHz, CDCl3) of (E)-methyl 2-(3-chloro-4-methoxyphenyl)-3-(3,4-dimethoxyphenyl)acrylate (3).
178

13

C NMR spectrum (125 MHz, CDCl3) of (E)-methyl 2-(3-chloro-4-methoxyphenyl)-3-(3,4-dimethoxyphenyl)acrylate (3).
179

1

H NMR spectrum (500 MHz, CDCl3) of methyl 7-chloro-2,3,6-trimethoxyphenanthrene-9-carboxylate (4).
180

13

C NMR spectrum (125 MHz, CDCl3) of methyl 7-chloro-2,3,6-trimethoxyphenanthrene-9-carboxylate (4).
181

1

H NMR spectrum (500 MHz, CDCl3) of (7-chloro-2,3,6-trimethoxyphenanthren-9-yl)methanol (5).
182

13

C NMR spectrum (125 MHz, CDCl3) of (7-chloro-2,3,6-trimethoxyphenanthren-9-yl)methanol (5).
183

1

H NMR spectrum (500 MHz, CDCl3) of 9-bromo-10-(bromomethyl)-2-chloro-3,6,7-trimethoxyphenanthrene (6).
184

13

C NMR spectrum (125 MHz, CDCl3) of 9-bromo-10-(bromomethyl)-2-chloro-3,6,7-trimethoxyphenanthrene (6).
185

1
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